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General IntroduCtIon
FunCtIonal perFormanCe In aGeInG
Functional performance declines with ageing. During the ageing process all tis-
sues and organ systems decline in function, resulting in a decreased functional 
reserve and a state of increased vulnerability. Key component in the functional 
decline in older persons is a decline in muscle mass and strength (sarcopenia). 
Sarcopenia is associated with various adverse health outcomes such as an in-
creased fall- and fracture-risk, poor quality of life and increased mortality risk(1). 
In this regard, vitamin D seems of particular interest because of the pleiotropic 
function of this hormone, which include effects on muscle, bone, neurons and 
vascular tissue. In addition, specific age-related changes occurring in the vita-
min D and calcium homeostasis lead to specific risks and deficiencies in older 
individuals, which contribute to the functional decline. 
VItamIn d 
Vitamin D is a fat soluble, seco-steroid hormone. Regulation of calcium and 
phosphate homeostasis is generally regarded as the traditional role of this hor-
mone. The main sources of vitamin D are cutaneous production, dietary intake 
and supplement use. After exposure to sunlight, the 7-dehydrocholesterol in 
the skin is converted to vitamin D3 under the influence of UV-B (290-315nm)
(2). The amount of vitamin D synthesized in the skin depends on environmental 
factors such as geographic latitude, season, and cloud coverage, and personal 
characteristics such as skin pigmentation, age and time spent outdoors. Further 
factors influencing vitamin D production in the skin are clothing (especially 
UV-protective clothing is now widely available) and use of sunscreen(3). Some 
dietary products contain natural vitamin D (either vitamin D2 (ergocalciferol) 
or D3 (cholecalciferol)), such as fatty fish and dairy products. It is estimated that 
sunlight supplies 90% of the vitamin D need, whereas dietary intake contributes 
just 10% of the vitamin D need(4). The precursors vitamin D3 or D2 are metabo-
lized in the liver to 25-hydroxyvitamin D3 (25OHD3) by the enzyme 25-hydroxy-
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lase. 25OHD3 is the main circulating vitamin D metabolite with a half life of 2 
to 3 weeks. This is the why serum 25OHD3 is regarded to best reflect a person’s 
vitamin D status(5). 
Next, 25OHD3 is converted into 1,25OH2D3, the most potent vitamin D 
metabolite, by the enzyme 1α-hydroxylase (CYP27B1). Most enzymatic 
1α-hydroxylase activity is located in the kidney, making this the most important 
organ for activation of the vitamin D metabolites. This 1α-hydroxylase process 
is tightly regulated by a feedback mechanism including parathyroid hormone 
(PTH) concentration, serum calcium concentration and fibroblast-growth-factor 
23 (FGF-23) expression(6). The 1α-hydroxylase enzyme is also expressed by 
other various tissues, such as osteoblasts, dendritic cells and keratinocytes(7, 8). 
This enables peripheral (extra-renal) 1,25OH2D3 formation and thus paracrine 
and autocrine effects. The majority (85-90%) of the circulating 25OHD3 and 
1,25OH2D3 is tightly bound to the vitamin D binding protein (DBP). In addition, 
about 10-15% of the metabolites is bound to albumin, leaving a small fraction 
of less than 1% as free, unbound vitamin D metabolites(9). It is thought that 
especially the unbound metabolites exert a biological effect. 
The vitamin D metabolites exert their effects via the vitamin D receptor (VDR) 
and this includes both genomic and non-genomic effects. Genomic effects of 
vitamin D are mediated by gene transcription and subsequent de novo protein 
synthesis. This process is initiated by the binding of the vitamin D metabolites 
to the high affinity nuclear VDR. The nuclear VDR is expressed in almost all tis-
sues and cell types(10, 11). The vitamin D receptor gene (VDR) is located on chro-
mosome 12 (12q13.1). After binding of 1,25OH2D3 to the nuclear VDR it forms 
a heterodimer with the retinoid-X receptor (RXR) protein. This heterodimer 
binds to a VDR-specific response element in the DNA and acts as a regulator of 
gene transcription(12). Non-genomic functions of vitamin D are generally rapid 
responses (minutes to hours). These responses are mediated by binding of vita-
min D metabolites to the plasma membrane associated VDR(13). The subsequent 
effects take place in the cytoplasm of the cell rather than in the nucleus. Plasma 
membrane associated VDR effects include modulation of intracellular calcium 
levels and activation of intracellular signaling cascades.  Non-genomic actions 
have especially been well-described in muscle tissue and in osteoblasts(8, 14). 
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aGeInG and VItamIn d
Ageing is associated with an increased risk for vitamin D deficiency. The esti-
mated prevalence of vitamin D deficiency in older persons ranges from 40-100% 
in community dwelling elderly men and women in both the US and Europe, 
depending on the definition and cut-off values used(15). In the Netherlands, a 
persons with a serum 25OHD3 level < 50nmol/l is generally considered vitamin 
D deficient. The high prevalence of vitamin D deficiency among older persons 
has several causes. The most important cause is probably a marked decrease in 
cutaneous vitamin D production capacity. Earlier studies in the 1980’s demon-
strated a more than twofold decrease in cutaneous vitamin D3 production ca-
pacity in older individuals as compared to young individuals which is due to an 
age-dependent decrease in epidermal pro-vitamin D3 (7-dehydrocholesterol) 
concentration(16). Other contributing causes to the high prevalence of vitamin D 
deficiency in older individuals are discussed in more detail in chapter 2.1
Ageing is also thought to be associated with a decreased efficiency of the 
vitamin D endocrine system and calcium homeostasis. For example, VDR expres-
sion in certain tissues has been reported to decrease with ageing, which could 
lead to a certain vitamin D resistance in older individuals(17, 18). Other reported 
effects of ageing that could decrease the efficacy of the vitamin D endocrine 
system and calcium homeostasis are an age dependent decrease in both renal 
and intestinal calcium channel expression and the increased prevalence of renal 
insufficiency in older persons which leads to a decrease in renal 1α-hydroxylase 
activity(18, 19). The precise effects of ageing on the vitamin D endocrine system 
and calcium homeostasis are also discussed in more detail in chapter 2.1. 
The high prevalence of vitamin D deficiency in old age, its causes, and effects 
have been known for many years now. In recent years vitamin D related research 
has generated much interest. This has resulted in guidelines, implemented care 
plans and protocols on the screening for, and treatment of, vitamin D deficiency 
in the Netherlands(20-22). However, despite these efforts, still many older persons 
remain untreated. It is unclear why, despite all these efforts, vitamin D deficiency 
is still so prevalent among older persons. A hypothesis could be that currently 
most studies, protocols and care plans focus on doctor-driven initiatives and 
interventions for the diagnosis and treatment of vitamin D deficiency. Patient 
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related factors are not, or scarcely studied. For example, no study examined 
the knowledge on vitamin D among older persons and if patient-knowledge 
on vitamin D is associated with vitamin D status or health behavior. Therefore 
we performed a study on knowledge of vitamin D among older persons, and 
studied the association with a person’s vitamin D status. This issue is discussed 
in more detail in chapter 2.2.
VItamIn d and FunCtIonal perFormanCe
Vitamin d and muscle function 
Mobility and muscle function decline with ageing(23). A key contributing factor 
in this process is the decrease in muscle mass and muscle strength, also named 
sarcopenia. Sarcopenia is a common condition in older adults. From approxi-
mately 40 years of age, a progressive loss of muscle mass occurs. Until the age 
of 70 years this loss is estimated at about 8% per decade and increases to about 
15% per decade in individuals over the age of 70. As a result, muscle strength 
declines with ageing(24, 25). The process of sarcopenia is generally thought to 
be multifactorial, influenced by environmental factors, disease triggers, inflam-
matory pathway activation, and hormonal factors(26). Vitamin D is, since long, 
considered important for muscle mass and muscle strength. The first observa-
tions between vitamin D deficiency and (neuro)muscular dysfunction date 
back to the fifties and sixties(27). The classical symptom of vitamin D associated 
myopathy is proximal muscle weakness. Other common symptoms include gait 
disturbances (“waddling gait”), and uniform generalized muscle wasting(28). 
With the identification of VDR expression in skeletal muscle cells, muscle tissue 
was recognized as a direct target tissue for vitamin D(29). Histological studies 
in human skeletal muscles demonstrate that vitamin D deficiency is associated 
with type II, fast twitch, muscle fiber atrophy(30). Other observed changes are 
enlarged interfibrillary spaces, increase in fat infiltration, fibrosis and accumula-
tion of glycogen granules(31). Additionally, several rapid, non-transcriptional ef-
fects of vitamin D on skeletal muscle cells have also been reported, suggesting 
that the membrane bound VDR is also expressed by skeletal muscle cells(13). 
Considering the significance of vitamin D for muscle function and mobility, it 
is important to recognize that a broad range of neurological effects of vitamin 
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D have been reported. Specific neurological effects of vitamin D, both on the 
central and peripheral nervous system, could also influence mobility. These 
neurological effects of vitamin D will be discussed in greater detail below.
In recent years many studies have been published that examine the associa-
tion between vitamin D status and muscle function(32). While some observational 
studies found no association, the majority of the observation studies did dem-
onstrate an association between vitamin D status and muscle function(33).  For 
example, in an observational study performed by Bischoff-Ferrari et al., higher 
serum 25OHD3 levels were associated with better lower-extremity function in 
persons aged ≥ 60 years. In this study that included 4100 individuals, subjects 
with serum 25OHD3 levels between 22.5 and 40nmol/l, had better lower ex-
tremity function compared to subjects with lower levels. This trend between 
lower extremity function and serum 25OHD3 levels was seen up to serum levels 
of 94nmol/l(34). In the prospective Longitudinal Aging Study Amsterdam, lower 
serum 25OHD3 levels were associated with a decrease in grip strength and ap-
pendicular muscle mass in older men and women during a three year follow up 
period(35). 
While the results of observational studies that examine the association be-
tween muscle function and vitamin D status are mostly consistent, the results of 
intervention trials that study the effect of vitamin D supplementation on muscle 
function are more inconsistent. While some studies reported an improvement 
of muscle function with vitamin D supplementation, other studies found no ef-
fect of vitamin D supplementation on muscle function or strength(33). Causes for 
the inconsistency of the trial results could be a difference in severity of vitamin 
D deficiency, differences in supplementation products or dosages, variation in 
co-morbidity or functional performance and variation in trial endpoints. 
To date, the optimal serum 25OHD3 level for muscle function is not known. 
Several reports suggest that 25OHD3 levels of up to 90nmol/l could be needed 
for optimal muscle function(36). However, these serum levels are not reached 
in many trials as many studies used low dose vitamin D supplementation. 
Therefore it could be hypothesized that high dose supplementation is prefer-
able for the treatment of vitamin D associated myopathy and that high dose 
supplementation results in a marked increase in muscle performance. The effect 
of high dose supplementation is discussed in more detail in chapter 3.2.
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Vitamin d and cardiovascular function
The incidence of cardiovascular events increases with ageing and coincides 
with the rising prevalence of vitamin D deficiency in older individuals.  In recent 
years, many studies reported on associations between vitamin D deficiency and 
a variety of cardiovascular risk factors and disease(37). Earlier studies demon-
strated that the prevalence of vitamin D deficiency is high among individuals 
with cardiovascular disease (CVS). In the National Health and nutrition Exami-
nation Survey (NHANES), 68-97% of the participants had serum 25OHD3 levels 
< 75nmol/l(38). The assumption that vitamin D status modulates cardiovascular 
risk is partly based on the fact that the enzyme 1α-hydroxylase is expressed 
in vascular smooth muscle cells (VSMC), endothelial cells, macrophages and 
dendritic cells, thereby enabling local 1,25OH2D3 production. Furthermore, the 
VDR is widely expressed by various tissues and cells of the cardiovascular sys-
tem including cardiac muscle cells, endothelium and vascular smooth muscle 
cells(37). 
In a study by Li et al., vitamin D has been shown to be a negative regulator 
of the rennin-angiotensin-aldosterone system (RAAS)(39). In another study, low 
vitamin D levels were associated with an increased activity of RAAS(40). In VDR 
knockout models there is an increase in the expression of rennin and conse-
quently of angiotensin II production, resulting in hypertension and cardiac 
hypertrophy[39). In 1α-hydroxylase knockout models, mice have elevated levels 
of rennin, hypertension and cardiac hypertrophy. This is reversed by treatment 
with 1,25OH2D3
(41). Furthermore, vitamin D is thought to play a pathophysi-
ological role in the development of both types 1 and 2 diabetes mellitus(42). 
Additionally, immune and inflammatory cells play an important role in CVD and 
the development of atherosclerosis(37). Various cells involved in the immune 
system such as macrophages, dendritic cells and activated T cells express the 
VDR. In general the effects of vitamin D are thought to by anti-inflammatory. 
For example, vitamin D down-regulates pro-inflammatory cytokines such as 
interleukin-1 (IL-1), IL-6, IL17, IL-23, tumor necrosis factor-α and interferon-γ, 
while anti-inflammatory cytokines such as IL-4 and IL-10 are up-regulated(43, 44). 
While cross sectional and observational data suggest an association between 
vitamin D status and cardiovascular heath, most intervention studies failed to 
demonstrate an effect. So, to date, the importance for vitamin D for cardio-
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vascular health is still subject of debate. In this thesis we study if all arteries, 
both central and peripheral, are affected in the same way by states of vitamin D 
deficiency in a cohort of older people. This is discussed in chapter 4.1. 
Vitamin d and neurological function
Several years ago, vitamin D was named a forgotten neurosteroid(45). Like 
other steroid hormones, vitamin D metabolites have been shown to cross the 
blood-brain barrier and are present in the cerebrospinal fluid(46). In addition, 
the enzyme 1α-hydroxylase is expressed throughout in the brain enabling 
1,25(OH)2D3 formation locally in the central nervous system (CNS). In 2005 
the VDR expression in the human brain was extensively mapped by Eyles et 
al. who demonstrated that the VDR expression, in addition to the enzyme 
1α-hydroxylase, is widely distributed throughout the adult human brain(47). 
VDR expression is especially prominent in the large (presumably dopaminergic) 
neurons within the substantia nigra, specific regions of both the hypothalamus 
and hippocampus, the prefrontal cortex, and the cingulate gyrus. 
In rodent models, including a VDR knockout model, it was demonstrated 
that vitamin D deficiency was associated with developmental abnormalities of 
the brain due to altered proliferation and differentiation(48). Specific effects of 
vitamin D have been reported on the regulation of neurotrophin production 
such as stimulation of nerve growth factor (NGF) production and stimulation 
of glial cell line-derived neurotrophic factor (GDNF)(49). Vitamin D has also been 
shown to inhibit nitric oxide production and decrease the production of various 
pro-inflammatory cytokines. In addition, a positive effect of 1.25(OH)2D3 on the 
acetylcholine pathway has also been reported suggesting an effect on specific 
neurotransmitters(50). The importance and clinical relevance of the VDR signaling 
within the central nervous system is still largely unclear. Early studies in animals 
have shown that vitamin D deficiency may increase the risk of brain dysfunc-
tion. In a recent study by Latimer et al., in aging rodents, a dose dependent 
improvement in cognitive function in response to vitamin D supplementation 
was seen. The suggested pathway was vitamin D mediated hippocampal gene 
expression that may improve the likelihood of successful brain ageing(51). In a 
recent study, the offspring of dams who were fed a vitamin D deficient diet un-
derwent a learning test. These mice from vitamin D deficient mothers exhibited 
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a learning disability at week 30 after birth. At week 70 after birth a significant 
loss in hippocampal volume was observed(52). Recent observational studies link 
vitamin D status to specific neuro-psychiatric disorders in humans. In a study 
by Ganji et al, conducted in 7.970 persons aged 15 through 39, the risk of de-
veloping a depression was higher in individuals with a vitamin D deficiency(53). 
In a study conducted in a group of older persons (aged 65-95 years) the risk 
of depression was associated with low serum 25OHD3 levels
(54). Studies also 
indicate a possible association of vitamin D deficiency with the development of 
Alzheimer’s disease and Parkinson’s disease(55). In this thesis we aim to get more 
insight in the association between vitamin D status and cognitive functioning 
and studied vitamin D status in patients with symptoms of cognitive decline. 
This is described in more detail in chapter 3.3.
aIms oF thIs thesIs
The objective of this thesis is to gain more insight into the pleiotropic functions 
of vitamin D in older adults, with an emphasis on mobility and neuromuscular 
function. In Section 2 the effects of ageing on the vitamin D endocrine system 
and calcium homeostasis are addressed. Ageing hampers the efficiency of these 
systems, leading to various health effects. Furthermore, the prevalence of vita-
min D deficiency among older persons is studied and in a search for explanations 
for the persisting high prevalence of vitamin D deficiency among older persons 
the knowledge on vitamin D among older persons has been evaluated. In the 
last chapters of this section,  trends regarding incidences of the most common 
osteoporotic fractures in the Netherlands were studied. In Section 3 the associa-
tion between vitamin D status and functional performance is described. In the 
first chapter of this section the association between vitamin D and neuromus-
cular functioning is studied, and in the second chapter the effects of high dose 
vitamin D supplementation on neuromuscular function is investigated. In the 
third chapter the association between vitamin D and cognitive functioning is 
assessed.  In Section 4 the associations between vitamin D status and vascular 
calcification are described. The possibility that specific arteries are affected dif-
ferently by vitamin D deficiency is examined. In Section 5, the reflection on our 
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main findings, speculation on the implication of our results and indications for 
future research are presented.
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abstraCt
Vitamin D is a fat-soluble, seco-steroid hormone. In man, the vitamin D receptor 
is expressed in almost all tissues, enabling effects in multiple systems of the hu-
man body. These effects can be endocrine, paracrine and autocrine. The present 
review summarises the effects of ageing on the vitamin D endocrine system and 
on Ca homeostasis. Furthermore, consequences for vitamin D supplementation 
are discussed.
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IntroduCtIon
Vitamin D is best known for its role in Ca homeostasis. Ageing affects both 
vitamin D metabolism and Ca homeostasis, with important consequences. In 
the present review, we outline new insights into the effects of ageing on both 
the vitamin D endocrine system and Ca homeostasis, which are relevant for 
clinicians who treat older people. Furthermore, considerations for vitamin D 
supplementation will be discussed.
VItamIn d metabolIsm
Vitamin D is a fat-soluble, seco-steroid hormone. The term vitamin D refers to 
two precursors, i.e. cholecalciferol and ergocalciferol. Cholecalciferol is mostly 
formed in the skin after exposure to sunlight. In the skin, the precursor 7-dehy-
drocholesterol is transformed into cholecalciferol under the influence of short-
wave UV light(1). Another source of vitamin D is the diet. Ergocalciferol is gener-
ated in yeast and plants and cholecalciferol is produced in fish and mammals. In 
general, oral vitamin D intake, especially in Europe, is low and depends mostly 
on cutaneous production of vitamin D for our reserves(2). The inert precursors 
are transported to the liver, where they are converted to 25-hydroxyvitamin 
D3 (25OHD3). In the kidney, 25OHD3 is hydroxylated by the enzyme 25OHD3-
1α-hydroxylase (1α-OHase) to form 1,25 dihydroxyvitamin D3 (1,25(OH)2D3), 
the most active vitamin D metabolite (Figure 1). 1α- OHase expression is not 
restricted to the kidney. Several cell types like macrophages, osteoblasts and 
neurons have also been shown to express 1α-OHase (Table 1)(3 – 5). 
The primary function of the vitamin D endocrine system is maintaining Ca 
and phosphate homeostasis. Vitamin D stimulates both intestinal absorption 
and renal reabsorption of Ca and phosphate. Vitamin D deficiency results in 
decreased Ca and phosphate (re)absorption and subsequently lower serum lev-
els of Ca and phosphate. This stimulates parathyroid hormone (PTH) secretion 
from the parathyroid glands(6). PTH stimulates renal 1α-OHase expression and 
1,25(OH)2D3 formation. PTH also stimulates osteoclast formation (osteoclasto-
genesis). Osteoclasts stimulate bone resorption, releasing Ca and phosphate 
ions from the bone into the blood. A recent animal study has demonstrated that 
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osteoclastogenesis was increased in mice when serum 25OHD3 levels were < 80 
nmol/l and this was positively associated with the receptor activator for NF-κB 
ligand/osteoprotegerin ratio. This increase in bone resorption was associated 
with the development of osteopenia and osteoporosis(7).
The optimal serum 25OHD3 level in human subjects to prevent stimulation of 
osteoclastogenesis is also believed to be about 80 nmol/l(7). 
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Figure 1  
 Figure 1. Different pathways for activation of vitamin D. Inert vitamin D precursors are either formed in 
the skin after exposure to UVB or derived from the diet. These precursors are hydroxylated in the liver to 
form 25OHD3. The 25OHD3 is bound to the vitamin D binding protein (DBP). The final 1-α- hydroxylation 
step which forms the most active vitamin D metabolite,1,25(OH)2D3 occurs either in the kidney (bulk) 
or in extra-renal cells expressing the 1-α-hydroxylase enzyme. The 1,25(OH)2D3 formation in the kidney 
is tightly regulated via a feedback mechanism and the active vitamin D formed in the kidney exerts 
endocrine effects after binding to the vitamin D receptor (VDR). The VDR forms a heterodimer with the 
retinoid receptor (RXR) and regulates gene transcription. The active vitamin D formed extra-renally 
exerts paracrine and autocrine effects. IFG, insulin-like growth factor; FGF, fibroblast growth factor; PTH, 
parathyroid hormone; 24,25(OH)2D3, 24,25-dihydroxyvitamin D3
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Other hormones that are known to stimulate renal 1α-OHase expression are 
insulin-like growth factor 1, calcitonin and oestrogen(8,9). Increases in serum 
Ca, phosphate and 1,25(OH)2D3 levels down-regulate renal 1α-OHase expres-
sion. Serum 1,25(OH)2D3 levels are also regulated by the enzyme 25OHD3-24 
hydroxylase (24OHase). Expression of 24OHase in the kidney is stimulated by 
1,25(OH)2D3 and this enzyme converts 1,25(OH)2D3 into less active metabolites. 
These feedback mechanisms play an important role in the protection against 
hypercalcaemia and hyperphosphataemia(10). 
Extra-renal 1α-OHase expression and activity is modulated differently from 
renal 1α-OHase and is less sensitive to feedback regulation by 1,25(OH)2D3
(11). 
It is suggested that induction of extra-renal 1α-OHase involves regulatory path-
ways that differ from the renal, cyclic AMP-mediated pathway. For example, in 
osteoblasts, 1α-OHase expression and activity is not influenced by the levels of 
1,25(OH)2D3, PTH and Ca like renal 1α-OHase. IL1β, an activator of NF-κB, stimu-
lates both 1α-OHase expression and activity in osteoblasts(4). In macrophages, 
immune signals such as TNFα and interferon-γ modulate 1α-OHase expression, 
while in vascular smooth muscle cells extra-renal 1α-OHase expression and activ-
ity is stimulated by the hormones PTH and oestrogen (Table 1)(12,13). Regulators 
of 1α-OHase expression and activity in most extra-renal tissues and the func-
tions of the extra-renally formed 1,25(OH)2D3 are still largely unknown. Some 
age-related effects on extra-renal 1α-OHase expression have been reported(14). 
In an animal model, ageing resulted in decreased bone 1α-OHase expression(15). 
Specific effects of ageing on the 1α-OHase expression and the activity in extra-
renal tissues and health consequences of alterations in 1α-OHase expression 
and activity with ageing remain to be elucidated. 
In recent years, several proteins have been discovered, which are important 
regulators of both Ca and phosphate homeostasis and the vitamin D endo-
crine system. These are fibroblast growth factor-23 (FGF-23) and klotho, a 
β-glucuronidase(16,17). FGF-23 is involved in the regulation of renal phosphate 
excretion. FGF-23 inhibits expression of the renal sodium-phosphate transport-
er and thereby increases phosphate excretion(18). In addition, FGF-23 decreases 
renal1α-OHase expression, stimulates 24OHase expression and decreases both 
PTH mRNA expression and PTH secretion from the parathyroid gland(18 – 20). This 
leads to lower 1,25(OH)2D3 levels and thus decreases vitamin D-related effects 
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on Ca and phosphate homeostasis. Klotho is involved in the regulation of renal 
Ca absorption and acts as a co-receptor or cofactor for other proteins such 
as FGF-23(21,22). Klotho is capable of binding to various FGF receptors and en-
hances FGF-23 signalling. FGF-23 and klotho thus have important functions in 
regulating Ca and phosphate homeostasis and are important for skeletal health, 
both via effects on the vitamin D endocrine system and via direct, non-vitamin 
D-dependent effects.
eFFeCts oF aGeInG on VItamIn d metabolIsm
Vitamin D deficiency is a worldwide problem(6). Although in Europe and the 
United States there has been strong attention on vitamin D in recent years and 
vitamin D-fortified food products are widely available, vitamin D deficiency is 
still very prevalent among older people(23 – 25). Mean serum 25OHD3 concentra-
Table 1. Extra-renal expression of the 1α-hydroxylase (1 α OHase) enzyme and effects of potential 
regulators relevant for ageing* 
Cells and tissues expressing
the 1α-OHase enzyme
Effects of potential regulators of 1α-OHase 
expression and/or activity
Placenta 1,25(OH)2D3:  ↓  
[107]
Keratinocytes TGFβ1:  ↑  [108] IFN- γ:  ↑  [109], 1,25(OH)2D3: - 
[110], 
TNFα : - [111], calcium: - [112], PTH:  ↑  [112]
Pancreatic cells -
Immune system 
(Monocytes/macrophages)
1,25(OH)2D3:  ↑  
[113], PTH: - [113],  TNFα :  ↑  [114], 
IFN-γ:  ↑  [115] 
Prostate cells 1,25(OH)2D3:  ↓  
[116], calcium: - [116] , PTH: - [116], 
EGF:  ↑  [117], eostrogenic compounds:  ↓  [118]
Osteoblasts 1,25(OH)2D3: - 
[4], PTH: - [4], calcium: - [4], 
 IL 1β:  ↑  [4], dihydrotestosterone:  ↑  (in males) [14], eostrogenic compounds:      
(in females) [14]
Colon epithelium 1,25(OH)2D3:  ↓   
[119] , TGFβ1:  ↑  (?) [120], dietary ca content: - [121]
Central nervous system 1,25(OH)2D3:  ↑  
[122]
Vascular endothelial cells and TNFα :  ↑  [123] , IFN-γ:   [123]
Vascular smooth muscle cells Eostrogenic compounds:  ↑  [12] , PTH:     [12]
Breast tissue 1,25(OH)2D3:  ↓   
[124] , 25OHD3:  ↑  
[125], 
eostrogenic compounds:  ↑  [126]
    * Based on ex vivo, in vitro and animal studies 
    1,25(OH)2D3, 1,25-dihydroxyvitamin D3; TGFβ1, transforming growth factor β1; IFN- γ,
     interferon- γ; PTH, parathyroid hormone; EGF, epidermal growth factor
     ↑  , Stimulating effect;  ↓  , inhibiting effect; -, no efffect 
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tions in The Netherlands in independent community-dwelling older people are 
about 30 nmol/l and in institutionalised older people about 20–25 nmol/l(26,27). 
Similar serum 25OHD3 levels among community-dwelling elderly have been 
reported in the United Kingdom and Germany(28,29). Reports suggest that 
serum 25OHD3 levels in older people in the United States are higher than in 
Europe(26,30,31). This is most likely due to higher oral intake of vitamin D in the 
United States where vitamin D fortification of food is more prevalent than that 
in Europe(24,32). However, even in the United States >50% of the community-
dwelling elderly are reported to have serum 25OHD3 levels < 75 nmol/l and 
about 30% of the elderly have levels < 50 nmol/l(30). 
The high prevalence of vitamin D deficiency in older people may have several 
causes. Cholecalciferol synthesis in the skin after sun exposure is less effective in 
old age because of a decline in cutaneous levels of 7-dehydrocholesterol(33). The 
level in a 70-year-old is only approximately 25% of the 7-dehydrocholesterol 
level in young persons(34). This is worsened by the decreased exposure to sun-
light with ageing due to immobility, lack of transport and social isolation(35,36). 
Another factor contributing to the increased risk of vitamin D deficiency is 
an increase in body fat with ageing. The increase in fat mass leads to a larger 
distribution volume for the fat-soluble 25OHD3, which decreases the bioavail-
ability of 25OHD3. Consequently, an inverse association has been demonstrated 
between BMI and both serum levels 25OHD3 and 1,25(OH)2D3 and a positive 
association between BMI and PTH levels has been demonstrated(37,38). 
An age-related decrease in 1,25(OH)2D3 levels has also been suggested but 
reports are conflicting(39). When vitamin D levels are low, compensatory hy-
perparathyroidism increases renal conversion of 25OHD3 to 1,25(OH)2D3 and 
thereby maintains normal or even slightly elevated levels of this metabolite. 
As vitamin D deficiency worsens, 1,25(OH)2D3 formation is impaired due to a 
lack of substrate(39). Additionally, several age-related effects have been reported 
that could lead to lower 1,25(OH)2D3 levels with ageing. First, renal function 
declines with age and this is accompanied with a decline in renal 1α-OHase 
activity and thus impaired conversion of 25OHD3 to 1,25(OH)2D3
(40). Second, 
levels of insulin-like growth factor 1, calcitonin and oestrogen, which stimu-
late 1α-OHase expression and activity, decrease with ageing(41). Furthermore, 
1,25(OH)2D3 metabolism may increase with ageing. In an animal model, an age-
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dependent increase in renal 24OHase expression was reported. This occurred 
predominantly in female animals, suggesting an effect of ovarian hormones(42). 
Ovariectomy in these animals was indeed associated with up-regulation of 
24OHase expression. Interestingly, the induction of 24OHase by 1,25(OH)2D3 
may also be affected by ageing(43).
eFFeCts oF aGeInG on VItamIn d aCtIon
The active metabolite 1,25(OH)2D3 exerts its function via the vitamin D recep-
tor (VDR), a nuclear receptor. Upon binding of 1,25(OH)2D3, the VDR forms a 
heterodimer with the retinoid receptor and binds to a vitamin D-responsive 
element in the promoter region of a target gene. This influences transcription 
of vitamin D-responsive genes(1). In addition, the functions of the VDR are not 
limited to the binding to vitamin D-responsive element. The VDR has also been 
found to bind β-catenin, a key transcriptional factor in the Wnt signalling path-
way(44,45). This pathway has been implicated in a number of malignancies. By 
binding to β-catenin, the VDR blocks its transcriptional activity and so exerts 
antiproliferative properties. Besides genomic effects via the VDR, 1,25(OH)2D3 
also exerts non-genomic effects via a membrane-bound plasma receptor or sec-
ond messengers such as cyclic AMP. These are rapid effects that do not depend 
on gene transcription. 
Almost all tissues and cells in the body express the VDR, including those not 
directly involved in the regulation of Ca homeostasis, enabling a broad range 
of effects. Extra-renal 1,25(OH)2D3 formation in various tissues implies that 
1,25(OH)2D3 is also capable of exerting paracrine and autocrine effects in addi-
tion to the well-known endocrine effects. Among the paracrine and autocrine 
effects are regulation of cell proliferation, differentiation and apoptosis(46). 
Alterations in VDR expression leading to vitamin D resistance with ageing have 
received particular interest. With ageing, a decrease in VDR expression in bone, 
intestine and muscle tissue has been reported(47 – 49). Various factors are known 
to influence VDR expression. Oestrogen, growth hormones and 1,25(OH)2D3 are 
stimulators of VDR expression but serum levels decrease with ageing(50,51). On 
the other hand, TNFα has been shown to down-regulate VDR expression, while 
serum TNFα levels increase with ageing(52,53). 
Effects on calcium homeostasis and considerations for vitamin D supplementation | 33
2.1
In addition to a decrease in VDR numbers, binding of 1,25(OH)2D3 to the 
VDR might also be decreased with ageing. A recent animal study, using com-
petition VDR-binding assays with [3H]-1,25(OH)2D3, has reported a decrease in 
1,25(OH)2D3 binding to the VDR with ageing in duodenal tissue
(54). Whether this 
also occurs in human subjects is not known.
parathyroId hormone and aGeInG
Like 25OHD3, PTH levels also exhibit seasonal variation with the highest PTH 
levels observed during the winter months(55). A (secondary) rise in PTH levels is 
generally observed with ageing with a prevalence varying from 20 to 60%(56). 
The most important causes of this secondary rise with ageing are vitamin D 
deficiency and resistance, renal insufficiency and low dietary intake of Ca(57). 
PTH stimulates 1,25(OH)2D3 formation and mobilises Ca from bone in order to 
maintain normal serum Ca levels(1). Hyperparathyroidism not only negatively 
influences bone health but also is associated with sarcopaenia and falls as PTH 
stimulates muscle protein breakdown(58). Furthermore, hyperparathyroidism 
has been related to cardiovascular events as PTH has been shown to promote 
vascular calcification(59). Recently, elevated PTH levels have been shown to be 
an independent predictor of impaired long-term survival prognosis in older 
people(56). High serum PTH levels (≥63 ng/l) were associated with significant 
increases in mortality (hazard ratio = 1.56, 95% CI: 1.29, 1.88) and a 2.3-year 
reduction of median life expectancy in a cohort of older patients(56).
CalCIum homeostasIs and aGeInG
Ca homeostasis involves a coordinated control of Ca handling by the intestine, 
kidney and bone under the influence of primarily PTH and 1,25(OH)2D3. Age-
ing, vitamin D deficiency and vitamin D resistance all affect these processes 
negatively. The two main mechanisms for Ca (re)absorption are a transcellular 
(active) and a paracellular (passive) route. The transcellular route involves entry 
of Ca into the cell at the apical side of the cell via Ca channels, diffusion of Ca 
through the cytosol bound to calbindins and active extrusion of Ca across the 
basolateral membrane via a Ca pump or a Na/Ca exchanger(57). The epithelial 
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Ca channels are members of the transient receptor potential (TRP) super family 
and more precisely, the vanilloid subfamily (TRPV). The TRPV5 channel is the 
major isoform in the kidney, while the TRPV6 channel is highly expressed in 
the intestine. The paracellular route involves diffusion of Ca via tight junctions 
between epithelial cells.
ageing and intestinal calcium absorption
An age-related decrease in intestinal Ca absorption has long been recognised(60). 
In the search for age-related factors that explain this decrease in absorption, 
attention has focused on TRPV6. A TRPV6 mouse knockout model illustrated 
the importance of TRPV6 for intestinal Ca absorption. In TRPV6 knockout mice, 
intestinal Ca absorption was decreased by 60%(61). Both in animal models 
and in human subjects, intestinal TRPV6 expression shows an age-dependent 
decline(48). This is probably due to several effects as TRPV6 expression is regu-
lated by 1,25(OH)2D3, oestrogen, PTH and dietary Ca intake
(57). Recently, animal 
models have shed light on the importance of vitamin D metabolites for TRPV6 
expression. Both in VDR and in 1α-OHase knockout mice, intestinal TRPV6 
expression is strongly reduced, which impairs intestinal Ca absorption(62,63). 
In addition, the ability of vitamin D metabolites to stimulate intestinal TRPV6 
expression also seems to decrease with ageing(64). 
The effects of ageing on TRPV6 expression differ among men and women. A 
recent study has reported that duodenal TRPV6 expression in both young and 
old men is strongly correlated with vitamin D status(48). In women, however, 
TRPV6 expression decreased with ageing but no correlation was found with 
vitamin D status. In women, there was an age-dependent decline in VDR expres-
sion in the duodenal biopsies that was not found in men, which could account 
for the reduced vitamin D responsiveness and thus lower TRPV6 expression 
in women(48). A possible explanation for decreased VDR expression could be 
decreased oestrogen levels with ageing. Oestrogen is important for vitamin D 
responsiveness as it stimulates both VDR and TRPV6 expressions(57). Although 
the strongest decline in intestinal Ca absorption is seen after the menopause 
due to decreasing serum levels of oestrogen, another late age-related decrease 
in intestinal Ca absorption, in addition to the decline that occurs at the meno-
pause, has also been reported in women after the age of 75(65). This decrease 
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in intestinal Ca absorption of nearly 30% was independent of serum levels of 
1,25(OH)2D3 and 25OHD3 and of renal function. The cause of this late decline 
in Ca absorption, which is most likely due to increased vitamin D resistance, 
remains to be clarified. 
In men, the importance of the sex hormone testosterone for Ca absorption is 
not well known and remains to be studied. A stimulating effect of testosterone 
on TRPV6 expression has been suggested(66).
ageing and renal calcium reabsorption
Less is known about the TRPV5 Ca channel. Like TRPV6, an age-related decrease 
in TRPV5 expression has been reported(67). Expression of TRPV5 is mainly regu-
lated by 1,25(OH)2D3, PTH and klotho
(16,68). Klotho is important for TRPV5 ex-
pression as it cleaves a carbohydrate residue from the Ca channel TRPV5, which 
increases TRPV5 expression and activity by trapping it in the plasma mem-
brane(16). Expression of klotho itself is positively regulated by 1,25(OH)2D3 and 
oestrogen(69). Several recent reports have demonstrated that klotho expression 
decreases with ageing(70,71). In linking klotho expression to renal Ca absorption, 
it has been speculated that klotho deficiency may result in the down-regulation 
of TRPV5 expression and thus impairment of renal Ca reabsorption(72). The im-
portance of TRPV5 for renal Ca reabsorption has recently been demonstrated. 
TRPV5 knockout mice have severe hypercalciuria and decreased serum Ca 
levels(73). Klotho knockout mice exhibit both decreased renal TRPV5 expression 
and decreased renal Ca reabsorption(74). 
As serum Ca levels normally fluctuate between narrow margins, interplay 
between intestinal Ca absorption and renal reabsorption is required. A de-
crease in renal Ca reabsorptive capability is compensated for by an increase 
in intestinal absorption. A recent animal model has demonstrated that TRPV5 
expression is an important determinant of TRPV6 expression. TRPV5 knockout 
mice have an increased intestinal TRPV6 expression and thus increased rate of 
intestinal Ca absorption(67). In double TRPV5 and 1α-OHase knockout mice, the 
up-regulation of intestinal Ca transport was abolished suggesting that this is a 
vitamin D-dependent effect(75). In patients with idiopathic hypercalciuria, a dis-
ease state characterised by decreased renal Ca absorption and high urine levels 
of Ca, a compensatory increase in 1,25(OH)2D3 levels and intestinal Ca absorp-
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tion is frequently observed(76). The relevance of this interplay for maintaining Ca 
homeostasis in older people and effects of ageing remain to be studied.
ageing and calbindins
Calbindins are cytosolic Ca-binding proteins. There are two major subclasses 
of calbindins: calbindin-D9k, which predominantly co-localises with TRPV6 in 
the small intestine, and calbindin-28k, which predominantly co-localises with 
TRPV5 in the kidney(57). Calbindins act to facilitate the diffusion of Ca through 
the cell interior towards the basolateral membrane. By buffering Ca, calbindins 
protect cells against toxic effects during states of high Ca influx. Anti-apoptotic 
effects of calbindins have been reported in different tissues such as neurons, 
osteoblasts and pancreatic β cells(10). Calbindin expression decreases with 
ageing, which could contribute to decreased Ca (re)absorption with ageing 
due to impaired transcellular diffusion(42). This is also influenced by vitamin D 
deficiency as vitamin D stimulates calbindin expression in both the intestine 
and the kidney(10).
other age-related effects on calcium absorption
PTH, besides stimulating intestinal Ca absorption via stimulation of renal 
1α-OHase activity and thus 1,25(OH)2D3 formation and subsequently TRPV5 and 
TRPV6 expressions, also has direct effects on Ca absorption. The stimulation of 
duodenal Ca uptake by PTH has been demonstrated in an animal model(77). In 
rat enterocytes, PTH enhances Ca influx through activation of the voltage-gated 
apical Ca channels and the cyclic AMP second messenger system. Interestingly, 
in aged duodenal cells, PTH is more efficient in stimulating Ca absorption when 
compared with duodenal cells of young rats(78). This is most likely due to altera-
tions in signal transduction via the PTH receptor that occur with ageing. It has 
been speculated that this increased efficiency is a compensatory mechanism in 
older people in states of impaired vitamin D status(57). 
Another determinant of Ca absorption is the bioavailability of dietary Ca itself. 
Low-Ca diets increase the efficiency of intestinal Ca absorption. The activities of 
all known genes involved in the transcellular pathway are enhanced by low-Ca 
diets, probably via activation of the vitamin D endocrine system(57).
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What Is VItamIn d deFICIenCy?
Measurement of serum 25OHD3 level is the best clinical indicator to assess 
vitamin D status. Serum 25OHD3 levels represent the combined contribution 
of both cutaneous synthesis and oral intake of the various dietary sources of 
vitamin D(79). Levels of 1,25(OH)2D3 are less suitable to assess vitamin D status 
because even in a state of vitamin D deficiency 1,25(OH)2D3 levels can be normal 
or slightly elevated. 
With the ever-increasing insights into the effects of vitamin D, optimal vitamin 
D status is becoming more difficult to define. Criteria and cut-off values for vita-
min D deficiency have mostly been linked to the effects of PTH levels on bone 
turnover. Serum 25OHD3 levels are inversely associated with PTH levels until an 
inflection point is reached. At this point, PTH levels begin to level off. Estimates 
for the serum 25OHD3 concentration at which the PTH concentration becomes 
constant vary from 25 to 122 nmol/l(80,81). This wide variation in estimates is due 
to inter-individual variation in Ca (re)absorption and vitamin D responsiveness, 
as previously discussed. Old people generally require higher serum 25OHD3 
levels, and thus vitamin D intake, to suppress PTH levels when compared with 
younger individuals. The capacity of the different vitamin D metabolites to raise 
serum 25OHD3 levels is unaltered with ageing
(82). 
When the effects on PTH levels and bone turnover are evaluated, serum 
25OHD3 concentrations of > 50nmol/l are regarded by many as sufficient
(83). 
However, when other health benefits of vitamin D are taken into account, in-
cluding its non-calcaemic effects, serum 25OHD3 concentrations of  > 75nmol/l 
are advised(84). In addition, the process of extra-renal 1,25(OH)2D3 formation 
and autocrine and paracrine effects are most efficient when serum 25OHD3 
levels are >75nmol/l(6). 
In many trials that study the effect of vitamin D supplementation, Ca intake is 
not measured, which complicates the comparison of individual trial results. Di-
etary Ca content has been shown to modulate the 25OHD3/PTH association
(81). 
As Ca intake is lower, higher 25OHD3 serum levels are required to normalise 
PTH concentrations. In part, this may also explain discordant results between 
intervention trials with vitamin D, as Ca intake differs among countries(85,86).
38 | Chapter 2.1
ConsequenCes oF VItamIn d deFICIenCy and 
resIstanCe
Vitamin D deficiency and resistance have important consequences for older 
people (Figure 2). To illustrate its importance, vitamin D deficiency is associated 
with an increased risk for nursing home admission. The hazard ratio of nursing 
home admission after 6 years of follow-up for vitamin D-deficient individuals 
(25OHD3 < 25 nmol/l) in a large cohort of older people was 3.48 (1.39–8.75) 
when compared with individuals with a high serum 25OHD3 level. The hazard 
ratio for vitamin D-insufficient individuals (25OHD3 = 25–49 nmol/l) was 2.77 
(1.17–6.55)(87). The effects of vitamin D on bone, intestine and kidney, which are 
regarded as the classical target tissues, have been the subject of many studies 
for a long period of time. However, as the VDR is being found in increasingly 
more tissues, implications of vitamin D in many different disease states are be- 
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Figure 2. Consequences of ageing on both vitamin D endocrine system and calcium absorption. 25OHD3, 
25-hydroxyvitamin D3; VDR, vitamin D receptor; 1,25(OH)2D3, 1,25-dihydroxyvitamin D; IGF, insulin-like 
growth factor; 24OHase, 24-hydroxylase; TRPV, transient receptor potential vanilloid; AID, auto-immune 
disorder
Effects on calcium homeostasis and considerations for vitamin D supplementation | 39
2.1
ing reported due to the effects of vitamin D outside these classical target tissues 
(Figure 2). Detailed effects of vitamin D have been reported on cardiovascular 
health, immune system, neurological diseases and cancer. The discussion of the 
effects of vitamin D in these disease states is beyond the scope of the present 
paper, but excellent reviews have recently been published(3,5,88,89).
Of note, recently adipose tissue has been shown to be a target tissue of 
vitamin D(90). With ageing, there is an accumulation of fat in bone marrow at 
the expense of osteoblastogenesis, contributing to the development of senile 
osteoporosis. Vitamin D has been shown to block adipogenesis by inhibiting 
the expression of PPARγ2, a critical transcription factor for adipogenesis in bone 
marrow(90). 
In general, the advancing knowledge of the effects of vitamin D in all these 
tissues further strengthens the call for adequate treatment of vitamin D defi-
ciency(91).
treatment oF VItamIn d deFICIenCy
Given the high prevalence of vitamin D deficiency in old age and the severe 
health consequences, a proactive approach from clinicians to case finding and 
adequate treatment of vitamin D deficiency is needed. Important considerations 
besides age are sex, BMI, skin colour, mobility, housing and dietary intake of both 
Ca and vitamin D(35,92,93). Giving individualised treatment advice is complicated 
by the fact that the ideal vitamin D level has not yet been defined and the treat-
ment effect on, for example, secondary hyperparathyroidism is also dependent 
on the dietary intake of Ca, which shows regional differences. In general, mobile, 
Caucasian community-dwelling elderly, who have a varied diet, need vitamin 
D supplementation of 10–20mg (400 IU–800 IU)/d to reach serum vitamin D 
levels of 50–75 nmol/l. Frail or institutionalised elderly on the other hand are 
suggested to need up to 50 mg (2000 IU)/d(84,94). The effectiveness of this high-
dose vitamin D supplementation in raising serum 25OHD3 levels adequately has 
been demonstrated in several clinical trials(95 – 97). However, robust evidence on 
the optimal dose of vitamin D supplementation in specific high-risk groups is 
still lacking. In a recent report by the Dutch Health Council(98), 20mg (800 IU) 
daily is advised for high-risk groups, i.e., persons with osteoporosis, residents 
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of care homes, women aged 50+ and men aged 70+ with dark skin colour or 
housebound individuals. 
Oral supplementation is the most effective intervention to treat vitamin D 
deficiency. Ergocalciferol is equally as effective as cholecalciferol in raising se-
rum 25OHD3 levels
(99). Daily dosing is the most efficient interval to raise serum 
25OHD3 concentrations when compared with weekly or monthly administra-
tion(26). 
Although vitamin D supplementation therapy is generally regarded as safe, 
cases of iatrogenic and accidental overdose with cholecalciferol have been 
reported(100,101). Most safety data concerning the use of high-dose cholecalcif-
erol supplementation come from observations in relatively young individuals. 
Few studies have used high-dose cholecalciferol supplementation for longer 
periods in frail, older patients. Frail old people, particularly the institutionalised, 
often have poor daily fluid intake, use diuretics and have less thirst sensation 
than younger persons. 
The need for high-dose supplementation therapy on the one hand, and the 
increased risk of dehydration on the other hand, may potentially increase the 
risk of accidental hypercalcaemia in these patients. Recently, concerns have risen 
regarding the possible negative health effects of vitamin D supplementation(88). 
The recent discovery of FGF-23 and klotho has given more insight into possible 
negative health effects of vitamin D supplementation and hypervitaminosis 
D. In animal studies, both FGF-23 and klotho knockout mice have increased 
expression of the enzyme 1α-OHase. These mice have increased serum levels of 
1,25(OH)2D3, Ca and phosphate and have overall an identical phenotype. These 
knockout mice, despite their high levels of 1,25(OH)2D3, develop osteoporosis, 
vascular and soft tissue calcifications, muscle wasting, pulmonary emphysema 
and have a shortened lifespan(102,103). Klotho knockout mice have very high 
levels of FGF-23 (about 2000-fold higher), but have no sign of phosphaturia, 
illustrating the importance of klotho for FGF-23 signalling(18,21). Normalisation 
of vitamin D activity in both klotho and FGF-23 knockout mice by either feeding 
them a vitamin D-deficient diet or knockout of the 1α-OHase enzyme increased 
survival and rescued most of the phenotype, illustrating that these effects are 
indeed vitamin D related(102,104). Similar effects of hypervitaminosis D due to 
accidental overdose in human subjects have been reported(101,105). Discontinu-
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ation of vitamin D supplementation in human subjects with hypervitaminosis 
D due to excessive intake of vitamin D resulted in normalization of serum levels 
of 25OHD3, gradual recovery of bone density mineral and normalisation of the 
ratio of urinary Ca to creatinine(106). So, when a patient is suffering from osteo-
porosis, clinicians should also consider, although rare, the possibility of vitamin 
D overdose.
ConClusIons
Vitamin D is a pleiotropic hormone. Besides the effects on classical tissues like 
bone and intestine, vitamin D has an effect on many more tissues. Effects of vita-
min D metabolites can occur via endocrine, paracrine or autocrine mechanisms. 
Ageing increases the risk of vitamin D deficiency and is associated with vita-
min D resistance and less efficient intestinal Ca absorption and renal reabsorp-
tion. Vitamin D supplementation doses needed to treat vitamin D deficiency 
and secondary hyperparathyroidism vary considerably between individuals. 
This makes it necessary for clinicians to give tailored advice to patients when 
treating hypovitaminosis D, taking into account these age-related effects and 
other characteristics that influence vitamin D status and Ca homeostasis. All cli-
nicians who frequently treat older patients should take a proactive approach to 
screening at-risk individuals for vitamin D deficiency, as this condition is still very 
prevalent. When treating patients for vitamin D deficiency, Ca intake should be 
assessed. Possible unwanted effects of long-term vitamin D supplementation 
and the effects of hypervitaminosis D should be studied in forthcoming trials.
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abstraCt 
Objective: The objective of the present study was to examine knowledge on 
vitamin D and calcium in a cohort of older adults and to test the association 
between health knowledge, vitamin D status and dietary calcium intake. 
Methods: The participants of this cross-sectional survey consisted of 426 
individuals (≥65 years), living in residential homes. Participants were tested for 
their knowledge on vitamin D and calcium using a standardized questionnaire. 
Serum 25-hydroxyvitamin D3 (25(OH)D3) levels and dietary calcium intake were 
measured. 
Results: The mean serum 25(OH)D3 level was 39.1 (±21.4) nmol/l and the 
mean daily dietary calcium intake was 826 (±242) mg/day. Of the participants, 
only 38 per cent indicated that they knew or had heard of vitamin D. Partici-
pants overestimated their daily calcium intake. Better knowledge on vitamin D 
and calcium was associated with both higher vitamin D levels (P < 0.001) and a 
higher daily dietary calcium intake (P < 0.001). 
Conclusion: Given the poor knowledge on vitamin D and calcium and the 
observed associations, improving health knowledge could be a possible inter-
vention to improve vitamin D status and calcium intake in older people. Further 
studies are needed to assess whether education will indeed lead to improve-
ment of vitamin D levels and calcium intake in this age group. 
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IntroduCtIon
Osteoporosis is a skeletal disease characterized by low bone mass and micro-
architectural dete rioration, which results in an increased bone fragility and 
fracture risk(1). The incidence of osteo porosis increases with age(2). Important 
risk factors for osteoporosis are vitamin D deficiency and a low dietary calcium 
intake(3). Especially among older people, vitamin D deficiency and low dietary 
calcium intake are very common(4). A possible contributing cause may be a lack 
of knowledge on vitamin D and calcium in this age group. Health knowledge, or 
literacy, is an essential requirement to allow people to make health-conscious 
decisions. Older people are a high-risk group for low health literacy(5). Data on 
knowledge among the general public, and older people in particular, about 
vitamin D and calcium is scarce. Studies that have been con ducted are gener-
ally telephone or online surveys among relatively young individuals(6–8). To the 
best of the authors’ knowledge, no study has specifically evaluated knowledge 
on vitamin D and calcium among older people, or examined the association 
between knowledge, vitamin D status and calcium intake.
In order to gain more insight in the effect of health literacy in this age group, 
we tested the pos sible association between health knowledge, vitamin D status 
and dietary calcium intake in a cohort of older persons.
methods
study participants
We performed a cross-sectional study among older people living in residential 
homes. Inclusion criteria were: no diagnosis of dementia (medical history) and 
aged 65 years and older. The study was approved by the Medical Ethics Commit-
tee of the Erasmus MC, University Medical Center Rotterdam (MEC-2007-160). 
Written informed consent was obtained from all participants.
baseline characteristics
Participants underwent a clinical assessment including medical history, biography, 
current physical complaints and medication use, including supplements. Informa-
tion on co-morbidities was obtained from the record of the residential home (phy-
sician) and this was cross-checked with information of the general practitioner. 
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Cognitive functioning was assessed using the Dutch version of the Mini-mental 
State Examination (MMSE), with a score ranging from 0 points (poor cognitive 
functioning) to 30 points (good cognitive functioning)(9). Dietary food intake was 
assessed using a 24-hour dietary recall questionnaire. Calcium intake in milligrams 
per day was calculated using the Dutch National Food Composition Table(10). In a 
randomly selected subgroup (~25 per cent) the 24-hour recall dietary assessment 
was repeated within several weeks after the initial visit. The correlation between 
the two measurements was 0.56, suggesting a moderate day-to-day variation, 
comparable with other reports(11). Serum 25(OH)D3 levels (in nmol/l) of all partici-
pants were measured using a radio-immuno-assay (DiaSorin, Stillwater, MN, USA). 
testing of knowledge on vitamin d and calcium
Participants were asked about their knowledge on vitamin D and calcium dur-
ing a structured face-to-face interview by the principal investigator (CO). The 
questions asked are shown in Addendum 1. Participants who reported knowing 
about vitamin D (positive response on either question 1 (unprompted) or 2 
(prompted)), were considered most knowledgeable on vitamin D (D+). Partici-
pants who responded negatively on both questions 1 and 2 were considered 
least knowl edgeable on vitamin D (D−). Participants were considered most 
knowledgeable on calcium (Ca+) when they answered questions 2, 3 and 5 
correctly (Addendum 1). Participants who did not answer these three questions 
correctly were considered least knowledgeable on calcium (Ca−).
Addendum 1. Questions asked 
Knowledge on vitamin D
1. Name any vitamin you know
2. Do you know or have you heard of vitamin D (if not mentioned in question 1)?
3. Do you think your vitamin D status is sufficient?
4. What is the most important source of vitamin D?
5. Name dietary sources of vitamin D?
6. What is the most important effect of vitamin D?
7.  Are you aware of the advice of the Dutch Health council regarding possible measures for the prevention of vitamin D 
deficiency?. If so, please name them.
Knowledge on calcium
1. Do you know or have you heard of calcium?
2. Name the most important dietary source of calcium?
3. What are the most important effects of calcium?
4. Do you think your dietary calcium intake is sufficient?
5. What is the daily recommended dietary calcium intake for individuals aged ≥ 70 years (in mg/day)?
6. Estimate your own daily dietary calcium intake (in mg/day).
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statistical analysis
Population characteristics were reported as mean ±SD. Baseline differences 
between the two groups (most or least knowledge) were tested using an inde-
pendent t-test for normally distributed variables (age, gender and MMSE score) 
and the Mann–Whitney test for skewed variables (cal cium intake and serum 
25(OH)D3 level). Secondly, the association between knowledge and vita min D 
status and calcium intake was tested using linear regression analysis. To account 
for potential confounding, we computed a multi-variate model containing 
covariates that were considered bio logically plausible (age, gender, education 
and MMSE score) or changed the point estimate by 10 per cent or more (none). 
Serum 25(OH)D3 level and dietary calcium intake were natural log trans formed 
given their skewed distributions. All statistical analyses were performed using 
SPSS software (version 16.1.1; SPSS Inc., Chicago, Illinois). A p-value of < 0.05 
was considered statistically significant.
results
In total 460 individuals met the inclusion criteria and, of those, 426 (93 per cent) 
consented. The mean age of the participants was 81.0 years (±7.2), and 73 per 
cent were female. Further popula tion characteristics are shown in Table 1. 
Table 1. Characteristics of the study population
Characteristic Participants 
(n = 426)
Range
(min – max)
Age, yr 81.0 ± 7.2 65 – 103
Female, n (%) 315 (73 per cent) -
Education, yr 8.7 ± 3.1 1 – 20
MMSE score (points) 26.5 ± 2.6 20 – 30
Serum 25(OH)D3 (nmol/l) 39.1 ± 21.4 9 – 153
Dietary calcium intake (mg/day) 826 ± 242 226 - 1345
Use of vitamin D/calcium prescribed, n (per cent) 51 (12 per cent) -
Use of vitamin D/calcium non-prescribed, n (per cent) 30 (7 per cent) -
Mean ± standard deviation (SD)
MMSE: Mini-Mental State Examination
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The mean (±SD) serum 25(OH)D3 level was 39.1 (±21.4) nmol/l. Of the partici-
pants, 285 (67 per cent) had 25(OH)D3 serum levels <50 nmol/l and 115 (27 per 
cent) had serum levels <25 nmol/l. The mean calcium intake was 826 (±242) mg/
day. A total of 132 (31 per cent) participants had a calcium intake of <700 mg/
day and 77 (18 per cent) had a calcium intake of >1200 mg/day.
Knowledge on vitamin D and calcium is shown in Table 2. Of the 426 par-
ticipants, 106 reported knowing about vitamin D without prompting and 55 
reported knowing about vitamin D after a prompt (total: n = 161/426; 38 per 
cent). Dietary products were considered as the most important source (n = 96; 
60 per cent). All participants (n = 426; 100 per cent) had heard of calcium. A 
total number of 351 (82 per cent) participants knew that calcium is important 
for bone health and 329 (77 per cent) knew that dairy products are the main 
dietary source for cal cium. The interrelation between estimated calcium intake 
and measured dietary calcium intake is shown in Table 3. In total 161 (38 per 
cent) participants were regarded most knowledgeable on vitamin D (D+). Like-
wise, 104 (24 per cent) participants were considered most knowledgeable on 
calcium (Ca+). The association between health knowledge and vitamin D status 
or calcium intake is shown in Figure 1. 
Table 2. Knowledge on vitamin D and calcium
Knowledge on vitamin D Knowledge on calcium
Having heard/learnt about vitamin D (n = 426) 
Unprompted
Prompted
Sources of vitamin D (n = 161; 38%)
Diet
Sun exposure
Don’t know sources of vitamin D / Other
Dietary sources of vitamin D (n = 96)
Dairy products
Fish
Don’t know any dietary sources / Other
Most important effect of vitamin D (n = 161)
Bone health
Immunity
Mobility/muscle strength/falls
Don’t know the effects / Other
Advice of the Dutch health council on the
prevention of vitamin D deficiency (n = 161)
Heard of the advice and named correct measure
Didn’t hear of advice or named wrong measure
106 (25%)
55 (13%)
96 (60%)
49 (30%)
16 (10%)
42 (44%)
22 (23%)
32 (33%)
54 (34%)
76 (47%)
22 (14%)
9 (5%)
23 (14%)
138 (86%)
Having heard/learnt about calcium (n = 426)
Positive response
Dietary sources of calcium (n = 426)
Dairy products
Meat
Fruit
Don’t know sources of calcium / Other
Most important effect of calcium (n = 426)
Bone health
Don’t know the effects / Other
Estimation of own calcium intake (n = 426)
Thinks calcium intake is sufficient
Thinks calcium intake not sufficient
Don’t know
Estimation of the recommended daily dietary calcium 
intake in mg/day for individuals aged ≥ 70 years (n = 426) 
< 700 mg
700 mg  – 1200 mg
> 1200 mg
Don’t know
426 (100%)
329 (77%)
23 (5%)
16 (4%)
58 (14%)
351 (82%)
75 (18%)
218 (51%)
153 (36%)
55 (13%)
69 (16%)
95 (22%)
107 (25%)
155 (36%)
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Participants in the group D+ had a mean serum 25(OH)D3 level of 58.5 (±17.7) 
nmol/l; in the group D− this was 27.4 (±13.5) nmol/l (P < 0.001). Among the 
participants that were consid ered D+, those who knew the advice of the Dutch 
Health Council on vitamin D had the highest serum 25(OH)D3 levels (mean: 67.4 
±16.5 nmol/l). The dietary calcium intake in the Ca+ group (1003 (±208) mg/
day) was significantly higher (P < 0.001) compared to the Ca− group (769 (±225) 
mg/day). Both the association between knowledge on vitamin D and serum 
25(OH)D3 levels and the association between knowledge on calcium and the 
daily dietary calcium intake remained signifi cant after exclusion of people that 
used either vitamin D and/or calcium supplementation. For both knowledge on 
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Figure 1. Baseline association of knowledge on vitamin D and calcium with vitamin D status and dietary 
calcium intake; * p < 0.001
Table 3. Interrelation between estimated calcium intake by participants and measured dietary calcium 
intake by 24-h recall
Estimated daily dietary calcium intake: n Measured daily dietary calcium intake n
< 700 mg/day: 52 < 700 mg/day
700 – 1200 mg/day
> 1200 mg/day
42
8
2
700-1200 mg/day: 89 < 700 mg/day
700 – 1200 mg/day
> 1200 mg/day
23
44
22
> 1200 mg/day: 138 < 700 mg/day
700 – 1200 mg/day
> 1200 mg/day
49
71
18
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vitamin D and knowledge on calcium, no association was observed with MMSE 
score or total years of education. 
Table 4 shows the regression model of the association between health 
knowledge and vitamin D status and calcium intake. After adjustment for pos-
sible confounders, the associations between health knowledge and the health 
outcomes remained significant.
dIsCussIon
The associations between health knowledge and serum 25(OH)D3 levels and 
dietary calcium were examined in a cohort of older persons. We demonstrated 
that better knowledge on vitamin D and calcium was associated with both 
higher 25(OH)D3 levels and a higher daily dietary calcium intake. Only a third 
of the participants were familiar with vitamin D and knowledge of sources and 
effects of vitamin D was poor. The importance of calcium for bone health was 
generally well known, but most participants were falsely under the impression 
that their dietary calcium intake was sufficient. 
Participants with the most knowledge on vitamin D (D+) had a serum 25(OH)
D3 level of 58.5 nmol/l, roughly twice as high as participants that had the least 
knowledge on vitamin D. The observed mean serum 25(OH)D3 level of 39.1 
nmol/l is in accordance with previous reports on the vitamin D status of older 
people, both from The Netherlands and other western countries(12,13). In The 
Netherlands, serum 25(OH)D3 levels of ≥50 nmol/l are currently recommended 
and in the United States levels of ≥75 nmol/l are advised(14,15).
Table 4. Regression analysis of vitamin D status and calcium intake according to health knowledge
Model 1 Model 2
B SE P-value B SE P-value
Knowledge on vitamin D 
Serum 25(OH)D3 level (nmol/l)
*
Dietary calcium intake (mg/day)*
Knowledge on calcium
Serum 25(OH)D3 level (nmol/l)
*
Dietary calcium intake (mg/day)*
0.837
0.098
0.255
0.288
0.049
0.031
0.071
0.032
< 0.001
P = .002
< 0.001
< 0.001
0.816
0.075
0.254
0.286
0.049
0.031
0.07
0.032
< 0.001
P = 0.01
< 0.001
< 0.001
Model 1: unadjusted
Model 2: adjusted for: age, gender, years of education, MMSE score
*Natural log-transformed
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The observed association was less obvious for individuals with either the most 
or the least knowledge on calcium. Although higher, the mean dietary calcium 
intake of 1003 mg/day in participants with the most knowledge on calcium 
(Ca+) was still below the recommended daily dietary calcium intake. The Dutch 
Health Council and the American Institute of Medicine cur rently recommend a 
daily calcium intake of 1200 mg/day for individuals ≥70 years(15,16). While low, 
the mean dietary calcium intake of 826 mg/day in this cohort is still higher than 
reported calcium intakes in older people in other countries, such as England, 
France, the United States and Austria, illustrating the large regional and cultural 
variance in dietary calcium intake(11,17–19). A large study from The Netherlands 
in non-institutionalized older people reported a daily dietary calcium intake 
of up to 1129 mg/day(20). Possible explanations for the difference between the 
reported intakes in the study by Koek et al. and our study could be a difference 
in age and frailty between the studied participants(20).
The observed association between health knowledge and vitamin D status 
and calcium intake in our study indicate a promising intervention possibil-
ity. Improving health knowledge in old age groups using guidance by health 
professionals has been shown to be beneficial in raising awareness of health 
concepts(21). In addition, a study by Engels et al. in a cohort of older persons 
demonstrated that inform ing participants about vitamin D increased the inten-
tion to start using vitamin D supplements(22). The intention to start supplements 
was especially high when patients received this advice from their own physician. 
In contrast, a recent study in young women found no effect of increasing knowl-
edge on vitamin D and calcium on dietary intake of vitamin D or calcium(23). 
In addition, the interrelation between knowledge and behaviour can also be 
conflicting. For example, a previous study on sunlight and vitamin D revealed 
a conflict between knowledge and behaviour. Individuals who were best aware 
of the benefits of sunlight, and the importance of vitamin D for bone health, 
tended to avoid sunlight most by using sunscreen and parasols, and staying 
indoors(24). This illustrates that ideally the effect of increasing health knowledge 
needs to be tested in a randomized controlled trial to ascertain a possible effect 
on vitamin D status and calcium intake. Multi-disciplinary teaching groups, tak-
ing into account a patient’s specific background and experiences, could perhaps 
be an effective method(25).
58 | Chapter 2.2
Our study has several strengths. This is, to the best of our knowledge, the first 
study on knowledge about vitamin D and calcium that examined the partici-
pants’ knowledge during a face-to-face inter view with the use of standardized 
methods. This is also the first study that assessed the interrelation of health 
knowledge with vitamin D status and calcium intake. Another strength of the 
present study is that participants were unaware of the study and its goals before 
the initial visit. Consequently, par ticipants were not able to prepare themselves 
for any of the questions. Furthermore, the participation rate of the individuals 
that were asked to participate in this study was high (93 per cent).
A limitation of the study is that because of the cross-sectional design, no cau-
sality can be con cluded regarding the association between health knowledge 
and vitamin D status and/or calcium intake. For example, better knowledge in 
patients using vitamin D or calcium supplements could be due to the use itself 
rather than that participants with more health knowledge started using supple-
ments. However, our finding remained significant after exclusion of participants 
that used vitamin D or calcium supplementation.
In conclusion, knowledge on vitamin D and calcium among this cohort of 
older persons was poor and this may have contributed to the high prevalence 
of vitamin D deficiency and low dietary calcium intake in this age group. In view 
of the severe consequences of vitamin D deficiency in old age, we feel that it 
is important to better inform older persons about the role and necessity of 
vitamin D and calcium, and to improve knowledge on current guidelines and 
possible preventative measures. Further studies are, however, needed to assess 
whether education will indeed lead to improvement of vitamin D levels and 
calcium intake in this age group.
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abstraCt
Background: Hip fractures are a public health problem, leading to hospitaliza-
tion, long-term rehabilitation, reduced quality of life, large healthcare expenses, 
and a high 1-year mortality. Especially older adults are at greater risk of fractures 
than the general population, due to the combination of an increased fall risk 
and osteoporosis. The aim of this study was to determine time trends in num-
bers and incidence rates of hip fracture-related hospitalizations and admission 
duration in the older Dutch population.
Methods and Findings: Secular trend analysis of all hospitalizations in the old-
er Dutch population (≥65 years) from 1981 throughout 2008, using the National 
Hospital Discharge Registry. Numbers, age-specific and age-adjusted incidence 
rates (per 10,000 persons) of hospital admissions and hospital days due to a hip 
fracture were used as outcome measures in each year of the study. Between 
1981 and 2008, the absolute number of hip fractures doubled in the older 
Dutch population. Incidence rates of hip fracture-related hospital admissions 
increased with age, and were higher in women than in men. The age-adjusted 
incidence rate increased from 52.0 to 67.6 per 10,000 older persons. However, 
since 1994 the incidence rate decreased (percentage annual change −0.5%, 
95% CI: −0.7; −0.3), compared with the period 1981–1993 (percentage annual 
change 2.3%, 95% CI: 2.0; 2.7). The total number of hospital days was reduced 
by a fifth, due to a reduced admission duration in all age groups. A possible 
limitation was that data were obtained from a linked administrative database, 
which did not include information on medication use or co-morbidities.
Conclusions: A trend break in the incidence rates of hip fracture-related hos-
pitalizations was observed in the Netherlands around 1994, possibly as a first 
result of efforts to prevent falls and fractures. However, the true cause of the 
observation is unknown.
The epidemic of hip fractures, are we on the right track? | 65
2.3
IntroduCtIon
Fall incidents and fall-related injuries among older people are a major public 
health problem in ageing societies worldwide(1-3). Of people aged ≥65 years 
approximately one third fall each year(4-7). Especially older individuals are at 
an increased risk of sustaining fractures after a low energetic trauma, e.g. a fall 
incident, due to underlying medical conditions, especially osteoporosis(8). 
Osteoporosis, a highly prevalent condition in the older population, is charac-
terized by low bone mass and micro-architectural deterioration of bone tissue. 
Osteoporosis results in an increased bone fragility and increased susceptibility to 
fractures(8). Typical sites of osteoporotic fractures include those of the hip, wrist, 
vertebrae, and upper arm(9). Approximately 85% of all hip fractures occur in indi-
viduals aged ≥65 years(10). Hip fractures are, more than any other type of fracture, 
associated with a loss of independence(11), morbidity(12), and mortality(13). 
Besides the health impact on the individual patient, the socioeconomic 
impact of osteoporosis and of hip fractures in particular is substantial(14). Hip 
fractures are currently leading to nearly half (46%) of all injury related health-
care costs in older adults in the Netherlands(15,16). In a global perspective, the 
annual estimated worldwide direct and indirect costs of hip fractures amounted 
to $34.8 billion in 1990, and are expected to rise to an estimated $131 billion by 
2050(17). With the expected continuing ageing of populations worldwide(18), it 
might be expected that the number of hip fractures will increase accordingly, 
making it necessary to prepare our healthcare systems for this burden. 
In order to optimize healthcare use and healthcare planning in an ageing 
society, accurate numbers in hip fracture incidence are mandatory. The aim of 
this study was to provide secular trends of age- and gender specific numbers, 
incidence rates and length of hospital stay (LOS) of hip fractures in the older 
Dutch population.
materIals and methods
For this study all data of hospital admissions due to a hip fracture in persons aged 
≥65 years were collected from 1981 throughout 2008 in the Netherlands. The data 
were retrieved from Statistics Netherlands (CBS, The Hague, The Netherlands), 
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which combines information of the National Medical Registration (LMR)(19) and the 
National Hospital Discharge Registry. Data regarding hospital admissions, admis-
sion diagnosis, LOS in days, age, and gender are stored in this database. The LMR 
database has a high nationwide coverage and nearly all admissions are stored in 
this database (less than five percent missing). Hospital admissions data and popu-
lation numbers were verified with the national Birth-Registry(19). The Birth-Registry 
is used to identify individual patients in the National Medical Registry. Data were 
corrected for missing values by the Statistics Netherlands, and extrapolated to full 
national coverage(20). A uniform classification and coding system is used by the 
LMR for all hospitals and did not change during the study period. Official coding 
clerks register the diagnosis and injury mechanism of all hospital admissions, 
based on data obtained from medical records. Throughout the study period, a 
hip fracture was defined by using the International Classification for Diseases, 9th 
revision of the World Health Organization, code 820. Older persons were defined 
as persons aged 65 years and older. Demographic numbers were retrieved from 
the Statistics Netherlands. In this study the mid-year population was used. The 
medical ethical review board of the Erasmus MC, University Medical Center, Rot-
terdam, approved the study (MEC-2010-402) and provided a waiver for ‘informed 
consent’, because the data were retrieved from a large public accessible database, 
containing anonymous data on admissions, which cannot be traced to individuals. 
Numbers of hospitalizations due to hip fractures were specified for age and 
gender. The age-specific incidence rates were calculated in 5-year age groups 
using the number of hip fractures in that specific age group, divided by the popu-
lation size within that specific age-group for male and female patients, and was 
expressed per 10,000 persons in that age-group. Age-adjusted incidence rates 
allowed us to compare the incidence rate for a standardized population during 
the study period, and were performed by ‘Direct Standardization’ to correct for 
demographic changes throughout the study period. Growth in the numbers of 
hospital admissions and LOS were calculated in percentages compared to the in-
dex year 1981. Data were analyzed using a Poisson regression analysis for annual 
growth in overall hospital admissions for older persons, corrected for population 
size and age composition. In order to model the trend in hospital admissions, a 
linear regression model with Poisson error and log link was built with log (mid 
year population size of each year of the study) as offset factor. To assess if the 
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annual growth changed during the study period for both genders, the Joinpoint 
Regression Program, Version 3.4.3. (Statistical Research and Applications Branch, 
National Cancer Institute, USA) was used. This program showed the necessity for 
assuming a spline instead of a simple linear model, for men and women separate-
ly, and determines where to place the knot. The spline function accommodated 
two piecewise linear fits, connected with one another at the knot. Comparison of 
these two periods enabled us to detect and quantify changes in the secular trend 
in admission rates such as stagnation or an increase in admission rates. The best 
knot was found to be January 1, 1994. The parameter for calendar year, corrected 
for gender and age-group was transformed into Percentage Annual Change (PAC). 
The analysis including splines yielded estimates of annual changes in admission 
rates within each period (1981–1993 and 1994–2008). All statistical analyses were 
performed using the Statistical Package for the Social Sciences (SPSS) software 
(version 16.1.1). A p-value <0.05 was considered statistically significant.
results
During the study period from 1981 throughout 2008, 355,320 patients aged ≥65 
years were admitted due to a hip fracture in the Netherlands. The annual num-
ber of hip fracture-related hospitalizations doubled in both men and women, 
from 7,614 cases in 1981 to 16,049 cases in 2008 (Table 1). The male:female ratio 
remained 1:3 throughout the study period. The crude incidence rate increased, 
from 46.4 per 10,000 older adults in 1981 to 66.5 per 10,000 in 2008 (an increase 
of 43.3% compared to 1981), and peaked in 1995 (70.4 per 10,000 older adults). 
Table 1. Population characteristics of persons aged ≥65 years, number, incidence and mean admission 
duration of hip fracture-related hospitalizations in persons aged ≥65 years (The Netherlands, 1981-2008)
Characteristic 1981 1986 1991 1996 2001 2006 2008
Population ≥65 yr (x 1,000) 1,642 1,769 1,934 2,061 2,175 2,330 2,415
Female (%) 59.0% 61.2% 60.2% 59.8% 58.9% 57.6% 57.0%
Admissions overall (n) 7,614 9,958 12,565 14,508 14,810 15,249 16,049 
- men (n) 1,857 2,281 2,879 3,326 3,385 3,845 4,105 
- women (n) 5,757 7,677 9,686 11,182 11,425 11,404 11,944 
Incidence rate† 46.4 56.3 65.0 70.4 68.1 65.4 66.5
Admission duration (days) 37.0 32.1 30.0 23.8 23.1 15.4 14.0 
† Crude incidence rate, expressed per 10,000 older adults
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For older men the crude incidence rate increased from 27.6 to 39.5 (an increase 
of 43.3%) and for older women from 59.5 to 86.8 (an increase of 46.0%) from 
1981 to 2008 respectively. 
Gender and age-specific incidence rates of hip fracture-related hospital 
admissions are shown in Table 2. For men and women aged 65–74 years the 
age-specific incidence rates of hip fractures did not change significantly when 
comparing 2008 to 1981. However, a strong increase (>50%) in the incidence 
rate of hospital admissions due to hip fracture was seen in men aged ≥80 years 
since 1981, up to an increase of 127% in men aged ≥95 years (from 156.3 per 
10,000 in 1981 to 354.7 per 10,000 in 2008). Age-specific incidence rates for 
women aged ≥75 years showed growth of one sixth to a quart.
The overall age-adjusted incidence rate of hip fractures increased (Figure 1) 
from 52.0 per 10,000 older adults in 1981 to 62.7 in 2008 (an increase of 20.6%). 
Throughout the study period, the age-adjusted incidence rate for women (68.6 
per 10,000 older women in 1981 and 79.9 in 2008) remained twice as high com-
pared to men (27.9 per 10,000 older men in 1981 and 37.8 in 2008).
The PAC, change per year, of the age-adjusted incidence rate was 1.13% (CI 
95%: 0.80; 1.45) for men versus 0.52% (CI 95%: 0.24; 0.81) for women over the 
whole study period. A joint-point regression analysis showed that the change in 
age-adjusted incidence rates was not constant over time and could be divided 
into two phases: first, the incidence of hospital admissions due to a hip fracture 
in older patients increased between 1981 and 1993, and second, decreased be-
tween 1994 and 2008 (Figure 1). The annual growth in men was 2.46% (CI 95%: 
1.98; 2.94) and in women 2.16% (CI 95%: 1.89; 2.43) in the period 1981–1993. The 
PAC decreased in the period 1994–2008 to a negative annual growth of −0.34% 
(CI 95%: −0.86; 0.19) in men and −0.64% (CI 95%: −0.83; −0.46) in women. 
Also the mean LOS decreased throughout the study period in both men and 
women, from 37.0 days in 1981 to 14.0 days in 2008 (Figure 2). 
The admission duration decreased over 60% in male and female patients 
of 65–79 years. Reduction in LOS was smaller in the older patient groups. In 
patients ≥80 years the LOS per admission was reduced by a third. In general, the 
LOS was age-related: the higher the age, the longer the admission duration (Fig-
ure 2). Although the total number of hip fracture-related hospital admissions 
increased, the total number of hospital-bed-days decreased due to a reduced 
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LOS per admission. The total numbers of hospital-bed-days are shown in Figure 
3 and decreased from 281,396 days in 1981 to 224,002 days in 2008 (a decrease 
of 20%). 
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 Figure 1. Absolute numbers, crude and age-specific incidence rates of hip fracture-related 
hoppitalizations in the Dutch population population  ≥65 years (1981-2008). Period 1 (dashed blue line): 
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Figure 2. Mean hospital admission duration in persons aged ≥65 years due to a hip fracture in the Netherlands 
between 1981-2008.* No SD data was available before 1991 
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For all men aged ≥65 years, the total number of hospital days decreased with 
8% (from 62,980 days in 1981 to 58,146 days in 2008). In women aged 65–79 
years, a reduction of 54% in hospital days was seen (from 94,903 days in 1981 
to 43,474 days in 2008). In women aged ≥80 years the number of hospital days 
increased until 1991 to 194,264 days and from there on started to decrease, with 
the total number of hospital days in 2008 (122,382 days) just below (−1%) the 
total number of hospital days in 1981 (123,513 days).
dIsCussIon
In order to determine trends in hip fractures in the older Dutch population, 
all hip fracture-related hospitalizations were analyzed from 1981 throughout 
2008. The age-adjusted incidence rates of hip fractures increased until the end 
of 1993 in the population ≥65 years. After that year, a trend break was observed 
and the incidence rates started to decrease. Although an encouraging decrease 
in the age-adjusted incidence rates was observed, the absolute number of hip 
fractures continued to increase due to a rising number of older persons in the 
population. 
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Comparable trends of decreasing incidence rates for hip fracture-related 
hospitalizations since the mid-nineties have been reported in several countries 
around the globe, such as the United States(21), Canada(22), and Finland(23). 
However, not all findings across western countries are consistent. A recent study 
from Germany failed to demonstrate a decline in hip fracture incidence rates(24). 
Since most studies on hip fracture incidence from multiple countries point in 
the same direction, there might be a causal explanation for this observation. 
However, there is no simple answer to this question, because risk factors for 
hip fractures are multifactorial, as mentioned by Leslie et al.(22) Important 
developments over the last two decades include: the increasing awareness of 
falls(25,26), the implementation of guidelines for the diagnosis and treatment of 
osteoporosis(27,28), increasing availability and use of bisphosphonates(29), and 
an improvement of calcium intake and vitamin D status, although the latter 
is argued by some(22). Other nationwide changes, such as the prevention and 
improved treatment of cardiovascular diseases in the general population may 
also have contributed to the observed trend break. A large Finnish twin-study 
recently demonstrated that cardiovascular diseases are associated with the 
development of hip fractures(30). However, the exact mechanism behind this as-
sociation is not clear yet(30). Another possibility might be that general health(31) 
and bone quality(32) have improved since smoking has been discouraged. The 
proportion of smokers is decreasing rapidly in the Netherlands(31,33) as well as 
in other countries(34,35). Furthermore, the Statistics Netherlands (CBS) reported 
that the mean body weight has increased in the Dutch population(33). An in-
creased Body Mass Index is associated with a lower fracture risk(36). 
A remarkable difference was observed between the younger and older age-
groups. Whereas incidence rates decreased in persons <80 years, the incidence 
rate stabilized in females aged ≥80 years, and continued to increase in males 
≥80 years. This finding is worrisome because the population of 80 years and 
over is the fastest growing segment in the ageing population(37) and because 
mortality and morbidity associated with hip fractures are greater for the old-
est old, and are higher in men than in women in the first year after sustaining 
a hip fracture(38,39). A possible explanation for this observation might be that 
life expectancy increased more rapidly in men compared to women over the 
past decades, resulting in a smaller gap in life expectancy between men and 
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women(40). Consequently, men have become more vulnerable for age-related 
(co)morbidities, such as osteoporosis and hip fractures, which were previously 
frequently seen in older women. This assumption is supported by a previous 
report on a more rapid increase in fall-related injuries, hospitalizations, and 
mortality in older men than in older women in the Netherlands over the past 
decades(1,41). Another possible explanation might be that osteoporosis in men 
is frequently underdiagnosed and undertreated(42). 
The number of hospital-bed-days per admission is considered to be one of 
the most important determinants of total costs per hip fracture in an individual 
patient(43). Therefore, a reduced LOS is necessary in order to reduce hospital 
care demands and to limit related healthcare costs. During the study period 
the LOS decreased by two-thirds. Several factors might have contributed to 
this impressive reduction: the rapid improvement of surgical and anesthetical 
care over the last decades, resulting in less invasive surgical procedures; the 
introduction of new hip prostheses, and implants; protocols for early timed 
surgery after a hip fracture; better pain management and better post-operative 
care with early mobilization; early discharge to designated rehabilitation places 
and skilled nursing homes; and the implementation of hip fracture treatment 
guidelines(44-46). In addition, during the final years of the study period a change 
in the financing structure of Dutch hospitals, which was introduced in 2004, 
may have led to a further decline in LOS. 
A strength of the present study is the availability of population-based in-
hospital data, covering a period of 28 years. The Dutch healthcare system is 
characterized by full health insurance coverage and full accessibility for the 
whole population during the study period. Since 1981 absolute numbers of hip 
fracture related hospital admissions and hospital-bed-days in all hospitals in the 
Netherlands have been recorded with nearly complete national coverage in a 
highly accurate electronic database. Throughout the study period, the coding 
system of the National Medical Registry did not change and no major policy 
changes were introduced in the Netherlands which might have affected the 
increase in admission rates. However, this study has some limitations. A pos-
sible limitation is that these data describe the situation in one country, which 
may not directly translate to other western countries, because of differences 
in healthcare system characteristics and demographics. Nevertheless, since 
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hip fracture trends(21,22,47) in other western populations are comparable with 
the trends in the Netherlands, there is no reason to assume that hip fractures 
trends will be substantially different in other countries. This study is based on a 
linked administrative database, which does not contain clinical data regarding 
underlying diagnosis, co-morbidity, injury severity, lifestyle, or medication use 
of the patients. This limits the interpretation of the causal mechanisms behind 
the observed trends. Furthermore, readmissions in one calendar year were not 
excluded and could potentially lead to some ‘double registration’. However, it is 
unlikely that readmissions influenced our results, since readmissions for injuries 
constitute at the most 2.6% (at the maximum) in the Netherlands, as was found 
in a study by Polinder et al(48). 
In summary, the increase in hip fracture incidence rates slowed down be-
tween 1981 and 1993, and the incidence rates started to decrease over the last 
14 years. However, incidence rates nowadays remain higher than in 1981, sug-
gesting that there is still room for improvement. Furthermore, the continuing 
increasing incidence rates in the oldest men is a worrying trend that deserves 
specific attention, since the group of persons aged 80 years and older are the 
fastest growing segment of aging societies. With the expected ageing of societ-
ies worldwide, continued attention is needed in order to cope with the demand 
of hip fracture related care in the near future.
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abstraCt
Background: Vertebral fractures are a common consequence of osteoporosis in 
older persons. With the ageing of the population, numbers are expected to rise.
Objective: To determine trends in health care demand due to vertebral frac-
ture related emergency department (ED) visits and hospitalizations in the older 
Dutch population. 
Design and setting: Secular trend analysis of vertebral fracture re-
lated ED visits between 1986 and 2008, using the Dutch Injury Sur-
veillance System. All ED visits with a primary diagnosis of a vertebral 
fracture in persons aged ≥65 years were extracted from this database. 
Main outcome measure: Numbers, age-specific and age-adjusted incidence 
rates (per 100,000 population) of ED visits and hospitalization rates due to 
vertebral fractures in the older Dutch population were calculated for each year 
of the study.
Results: The total number of ED visits due to a vertebral fracture increased 
from 913 in 1986 to 2,502 in 2008 (174% increase). The majority of fractures 
were caused by a low-energetic fall incident (83%). The overall age-adjusted 
incidence rate increased from 51.6 per 100,000 population in 1986 to 103.6 in 
2008. Incidence rates increased with age and were higher in females than in 
males. The hospitalization rate remained stable at about 50-55%, in both fe-
males and males.  
Conclusion: Vertebral fracture related ED visits and hospitalizations are 
increasing rapidly in the older Dutch population, especially in the oldest-old. 
Most vertebral fractures were associated with falls. These findings indicate that 
a pro-active approach in the diagnosis and treatment of osteoporosis and in the 
prevention of falls in both men and women is warranted. 
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IntroduCtIon
Osteoporosis is a growing public health concern in developed countries 
worldwide(1). It is a skeletal disease, characterized by low bone mass and micro-
architectural deterioration, which results in an increased bone fragility and 
fracture risk(2). Vertebral fractures are one of the most common osteoporotic 
fractures. Approximately 90% of vertebral fractures are associated with osteo-
porosis(3). Vertebral fractures lead to functional impairment, impaired quality of 
life and increased mortality(4-7). A previous vertebral fracture is associated with 
an increased risk of further vertebral fractures and hip fractures(8). 
It was estimated that in the year 2000, nine million osteoporotic fractures 
occurred worldwide, and of these approximately 1.4 million (15%) were clinical 
vertebral fractures(9). The majority of vertebral fractures however are morpho-
metric, i.e. clinically silent. The prevalence of radiographically identified verte-
bral deformities has been estimated to be 5% between the age of 50-54 years, 
and rises to 50% at age 80-84 years(10).
The number of patients with a vertebral fracture is expected to increase 
because of the increasing life expectancy and the increasing number of osteo-
porotic individuals in the population(11-13). However, there are few data on time 
trends of healthcare demand due to clinical vertebral fractures. The aim of this 
study was to analyze time-trends in clinical vertebral fractures by analyzing 
trends in emergency department (ED) visits and hospitalization rates after ED 
visit. 
methods
Data on ED visits due to a vertebral fracture in the Dutch population aged 65 
years and over was extracted from the Dutch Injury Surveillance System (LIS). 
The LIS database is a continuous monitoring system in which injury diagnoses 
and injury mechanisms are registered by using the International Classification 
of Diseases of the World Health Organization (ICD 10th revision)(14). LIS is based 
on 13 geographically distributed EDs in the Netherlands, resulting in a repre-
sentative 12% sample of injury-related ED visits. Numbers were extrapolated to 
national estimates. An extrapolation factor was calculated by the Consumer and 
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Safety Institute (Amsterdam, the Netherlands) based on the adherent population 
of the participating hospitals and Dutch population numbers in each year of the 
study. The database makes it possible to measure and describe healthcare use 
during a specific period. The full-model description has been published by the 
Consumer and Safety Institute, Amsterdam and has been used previously(15-17). 
The model was applied to all persons aged 65 years and older who attended 
an ED between 1986 and 2008. A vertebral fracture was defined using the ICD 
10th revision(14). Vertebral fractures were selected based upon the registered 
primary diagnosis in the LIS. In case of multiple injuries, the primary injury in 
LIS was determined by application of an algorithm giving priority to spinal cord 
injury, skull and brain injury, and lower extremity injury above injuries in other 
body parts, and to fractures above other types of injury to determine the most 
serious injury. Numbers of ED visits due to vertebral fractures were specified for 
age and gender. Furthermore, discharge was registered as treated-and-released 
or treated-and-admitted to calculate the admission rate. Age-specific rates were 
calculated in 5-year age groups. The overall age-adjusted incidence rate for the 
population aged 65 years and older was calculated by using “Direct Standard-
ization” to correct for changes in demographics. Incidence rates were expressed 
per 100,000 person years. A linear regression analysis was used to analyse the 
age-adjusted incidence rate of vertebral fracture related ED visits over time. The 
statistical analyses were performed using the Statistical Package for the Social 
Sciences (SPSS) software (version 16.1.1). A p-value <.05 was considered statisti-
cally significant.
results
From 1986 throughout 2008, the population aged ≥65 years increased from 
1.6 million to 2.4 million persons in the Netherlands. During that same period, 
a total number of 31,650 patients were seen and diagnosed in the ED with a 
vertebral fracture. The annual number of vertebral fractures requiring ED visits 
increased with 174% (from 913 in 1986 to 2,502 in 2008), Table 1. 
The majority (83%) of vertebral fractures was related to falls in both males 
and females; this remained unchanged throughout the study period (Table 2). 
The epidemic of hip fractures, are we on the right track? | 83
2.4
Gender and age-specific incidence rates are shown in Table 3. Incidence rates 
increased with ageing and were higher in women than in men for all age groups. 
The crude incidence rate for men increased from 39.3 per 100,000 older adults 
in 1986 to 82.7 in 2008 (110% increase). The crude incidence rates for women in-
creased from 59.9 per 100,000 older adults in 1986 to 119.4 in 2008 (99% increase). 
Figure 1 shows the age-specific incidence rate of vertebral fractures according to 
5 year age groups for the periods 1986-1988 and 2006-2008, respectively. 
Table 1. Population characteristics of persons aged ≥65 years, number, incidence, and admissions due to 
a vertebral fracture (The Netherlands, from 1986 throughout 2008)
Charactaristic 1986 1991 1996 2001 2006 2008
Population ≥65 yr (*1,000) 1,769 1,934 2,061 2,175 2,330 2,415
Population female, % 61.2 60.2 59.8 58.9 57.6 57.0
ED incidence rate† 51.6 56.6 65.9 60.3 83.1 103.6
ED visits, No. 913 1,095 1,358 1,311 1,938 2,502
- Female, No. (%) 634 (69) 789 (72) 981 (72) 816 (62) 1,328 (69) 1,643 (66)
Hospitalization rate† NA 32.6 36.0 30.0 42.2 57.5
Hospitalized, No. (%) NA 631 (58) 741 (55) 643 (49) 984 (51) 1389 (55)
- Females, No. (%) NA 445 (71) 510 (69) 392 (61) 622 (63) 905 (65)
 † Crude incidence rate, expressed per 100,000 older adults; NA, not available
Table 2. Causes of vertebral fractures requiring ED attendance between 1986-2008 in older adults aged 
65 years and over in the Netherlands
Trauma mechanism Males Females Overall
n % n % n %
Fall 7,736 78.7% 18,390 84.3% 26,126 82.5%
MVA 1,481 15.1% 1,835 8.4% 3,316 10.5%
Other 610 6.2% 1,598 7.3% 2,208 7.0%
Total 9,826 100% 21,823 100% 31,650 100%
MVA, Motor Vehicle Accident
Table 3. Age-specific incidence rates for vertebral fractures related ED visits in persons ≥65 years, per 
100,000 older persons (The Netherlands, from 1986 throughout 2008)
Age-group, year
Period 65-69 70-74 75-79 80-84 ≥85
men women men women men women men women men women
1986-1990 33.4 38.8 18.9 60.0 58.6 90.7 53.1 95.3 89.5 88.9
1991-1995 17.2 29.8 25.0 40.0 37.1 62.6 48.3 75.3 123.0 124.4
1996-2000 29.8 54.6 33.5 60.0 47.4 69.5 89.2 125.6 151.8 123.1
2001-2005 35.4 37.1 40.2 58.3 59.7 82.3 73.3 94.9 106.1 140.7
2006-2008 51.5 58.4 61.3 70.8 77.9 112.2 113.8 141.0 216.8 222.8
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The strongest increase in incidence rate occurred in women ≥85 years, from 
88.9 per 100,000 during the period 1986-1990 to 222.8 per 100,000 during 
the period 2006-2008 (150% increase). The overall age-adjusted incidence 
rate for ED visits due to vertebral fractures in older adults increased from 51.9 
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Figure 1. Incidence rate (expressed per 100,000 population) of vertebral fracture related ED visits in the 
Netherlands per 5 year age-groups; 1986-1988 and 2006-2008  
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Figure 2. Age-adjusted incidence rate (expressed per 100,000 older persons) of vertebral fracture related 
ED-visits in persons 65 years and over. The Netherlands, 1986 throughout 2008. The line indicates the 
age-adjusted incidence rate of ED visits due to a vertebral fracture and the gray area the 95% confidence 
interval of the linear regression analysis (Trend is significantly different as zero, p<.001 for both lines)
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to 102.3 per 100,000 persons (increase 97%) throughout the study period. 
The age-adjusted incidence rate in women increased from 59.9 per 100,000 
population in 1986 to 116.3 in 2008. For men the age-adjusted incidence rate 
increased from 39.7 in 1986 to 81.2 per 100,000 population in 2008 (Figure 2).
During the period 1991-2008 14,658 patients were admitted to the hospital after 
being diagnosed with a vertebral fracture at the ED. The absolute number of hos-
pital admissions increased from 631 in 1991 to 1,389 in 2008 (120% increase). The 
overall percentage of patients admitted from the ED during the whole period was 
56%. The percentage of hospital admissions did not change over time and remained 
between 50-55% for both men and women during the study period (Table 1).
The adjusted incidence rate of hospital admission after an ED visit for a vertebral 
fracture increased from 32.6 per 100,000 population in 1991 to 57.1 in 2008. 
The incidence rate increased most in the age group 85-89 years, from 46.2 per 
100,000 population in 1991 to 152.0 in 2008 (229% increase).
dIsCussIon
The aim of this study was to gain insight into secular trends of health care de-
mand due to vertebral fracture related ED visits in the older Dutch population. 
From 1986 to 2008 the absolute number of vertebral fractures requiring an ED 
visit increased by 174% to over 2,500 ED visits per year. The age-adjusted inci-
dence rate for ED visits nearly doubled (97% increase) over the last two decades. 
Especially a strong increase in vertebral fracture related ED visits was seen in 
individuals aged 80 years and over. The hospital admission rate for people di-
agnosed with a vertebral fracture at the ED remained fairly constant during the 
study period at about 55% for both men and women. In over 80% of the cases, 
the vertebral fracture was related to a fall incident.
Data on clinical-epidemiological characteristics of vertebral fractures are 
scarce and, as far as we are aware, this is the first study to report on national 
data regarding vertebral fracture related ED visits and hospital admissions with 
a study period of over two decades. Some studies with a shorter follow-up have 
examined incidence rates of vertebral fracture related hospital admissions(18,19). 
Vertebral fractures in Spain led to a hospitalization rate of 27.6 per 100,000 
population for individuals aged ≥30 years in the year 2002, with a peak of 108.2 
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per 100,000 population among individuals aged 80 years and over(18). The Span-
ish study showed that vertebral fractures affected predominantly women with 
a female:male ratio of 1.5:1, which is in line with our data. A second study from 
the United States reported on vertebral fracture related hospital admissions 
from 1993 throughout 2004. In this study the admission rate increased from 
160.9 per 100,000 United States population in 1993 to 180.9 in 2004(19). In ad-
dition, several studies examined the incidence rate of radiographical vertebral 
fractures in older individuals. In the Rotterdam Study, an ongoing cohort study 
in over 7,000 older individuals, the incidence of a radiographically diagnosed 
vertebral fracture in men aged 65-75 years was 5.1 per 1000 person years. In 
men aged 75 years and over, the incidence rose to 9.3 per 1000 person years. 
In women, the incidence was 17.0 in those aged 65-75 years and 19.6 per 1000 
person years in those aged 75 years and over(20). 
In the current study, numbers of fall-related and non-fall related vertebral 
fractures increased equally as strong. The observed increase in both fall- and 
non-fall related vertebral fractures might have several causes. An important 
cause for the observed increase in number of vertebral fractures might be the 
ageing of the population(13). Nowadays people live longer, often with multiple 
medical problems(21). Ageing and frailty are both risk factors for an increased fall 
risk and for osteoporosis, and could thus contribute to an increase in vertebral 
fracture incidence. In the present study, about 80% of the vertebral fractures 
diagnosed at the ED were fall related. In the literature it has been estimated that 
about 75% of all vertebral fractures that come to clinical attention are precipi-
tated by routine daily activities such as bending, making beds or lifting (light) 
objects, and that only 25% of all vertebral fractures in older people is the result 
of a fall-incident(4). It can be postulated that fall-related vertebral fractures are 
over-represented because the ED was taken as intake point in our study. Given 
the fact that a substantial proportion of the acute hospital care for vertebral 
fractures is fall-related, it seems plausible that in order to reduce the burden of 
vertebral fracture related acute admissions, the focus should not only be on the 
treatment of osteoporosis, but also on the reduction of falls in older persons. 
While vertebral fractures are the most common osteoporotic fracture, hip 
fractures are the second most common osteoporotic fracture, and data on time 
trends of hip fracture is more readily available. Recent data on secular trends 
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of incidence rates for hip fractures reported a trend break in incidence rates of 
hip fracture in the United States(22). Since 1995, incidence rates of hip fracture 
started to decline in the American population aged ≥65 years, and similar results 
are reported in a Canadian study(23). A similar trend break for vertebral fractures 
was not found in the current study.
The strength of the present study is the availability of continuous ED monitor-
ing system for an extensive period of 22 years. Throughout the study period, 
no major policy changes that might have affected the increase in admission 
rates were introduced in the Netherlands. The Dutch health care system was, 
and continues to be, characterized by full health insurance coverage and 
full accessibility for the whole population. Furthermore, the coding system 
of the LIS did not change during the study period and takes place by official 
trained coding clerks. A limitation of the use of this linked administrative 
database is that it does not contain data regarding underlying diagnosis, co-
morbidity, treatments or medication use. This hampers the interpretation of 
causal mechanisms behind the observed trends. Furthermore, readmissions in 
one calendar year were not excluded and could potentially have led to some 
“double registrations”. However, readmissions have been shown to contrib-
ute to only 2.6% of all injury related hospitalizations in the Netherlands(24). 
The true burden of vertebral fractures in the older Dutch population will 
probably exceed the numbers as presented in our study, since only a third of 
all vertebral fractures are currently diagnosed in clinical practice(25). This low 
percentage is partly due to under-diagnosis, especially in the oldest old, and to 
the atypical presentation of patients with a vertebral fracture(26). 
In conclusion, the incidence rate of ED visits in the Netherlands due to a 
vertebral fracture in persons aged 65 years and over, doubled in the period 
from 1986 throughout 2008. The increase was most pronounced in the oldest 
old. A fall was the most frequent cause. This should be a further imperative to 
a pro-active approach in the diagnosis and treatment of osteoporosis and the 
prevention of falls in both men and women.
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abstraCt
Objectives: To investigate whether serum 25-hydroxy vitamin D (25(OH)D) is 
associated with physical performance in men and women.
Design: Cross-sectional.
Setting: Emergency departments (EDs) of five hospitals.
Participants : Older adults who visited an ED because of a fall (N = 616).
Measurements: Physical performance was assessed using the Timed Up and 
Go Test, the Five Time Sit to Stand Test, handgrip strength, and the tandem stand 
test. Multivariate linear regression was used to assess the association between 
physical performance and log-transformed 25(OH)D concentration adjusted for 
potential confounders.
Results: In men, higher serum 25(OH)D concentration was significantly as-
sociated with better handgrip strength (regression coefficient (B) = 3.86, 95% 
confidence interval (CI) = 2.04 - 5.69), faster TUG time (B = - 2.82, 95% CI = - 4.91 
to - 0.73), and faster FTSS time (B = - 3.39, 95% CI = - 5.67 to - 1.11). In women, 
higher serum 25 (OH)D concentration was significantly associated with faster 
TUG time (B = - 2.68, 95% CI = - 4.87 to - 0.49).
Conclusion: A positive association was found between serum 25(OH)D level 
and physical performance in men and women. Intervention studies are needed 
of vitamin D–deficient older men and women to further investigate the effect of 
vitamin D supplementation in this group.
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IntroduCtIon
Muscle tissue is an important target tissue for vitamin D(1), and vitamin D 
deficiency is an important contributor to decline in physical performance and 
increase in fall incidence(2-9), but most studies demonstrating the relationship 
between serum 25-hydroxyvitamin D3 (25(OH)D) levels and physical perfor-
mance have been conducted in female-only populations(5-8). Studies in men 
have shown positive or no associations(2,10-12), but most of these studies have 
been conducted in a population of highly functional, younger men with a low 
prevalence of vitamin D deficiency. In addition, large studies involving men 
were population-based, epidemiological studies in randomly selected, nons-
ymptomatic older persons(2,12) and have not focused specifically on individuals 
with possible symptoms of neuromuscular dysfunction, such as falls. A fall is 
generally considered to be a common symptom of neuromuscular dysfunction 
and vitamin D deficiency(1). The current study assessed whether serum 25(OH)
D was associated with physical performance in community-dwelling older men 
and women who visited a hospital emergency department (ED) after experienc-
ing a fall.
methods
data collection
Baseline data from the Improving Medication Prescribing to reduce Risk Of Falls 
(IMPROveFALL) study were used, a detailed description of the methods can be 
found elsewhere(13). In short, individuals aged 65 and older who visited the ED 
because of a fall, used one or more fall–risk increasing drugs, had a Mini-Mental 
State Examination (MMSE) score of at least 21 of 30 points(14), were able to walk 
independently, were community dwelling, and provided written informed con-
sent were eligible for enrollment. Enrollment started in October 2008 and was 
completed in October 2011. The medical ethics committee of the Erasmus MC 
University Medical Center approved the protocol.
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Covariates
A fall was defined as coming to rest unintentionally on the ground or a lower 
level with or without losing consciousness but not induced by an acute medical 
condition (e.g., stroke) or an exogenous factor such as a traffic accident(15). A 
geriatric assessment was performed at baseline. Medical history, prescription 
medication, supplements, and lifestyle factors (e.g., education, smoking, alcohol 
intake) were documented. The number of comorbidities (any malignancy, dia-
betes mellitus, cardiac disease (hypertension, myocardial infarction, cardiomy-
opathy, congestive heart failure, arrhythmia, valve disease), chronic obstructive 
pulmonary disease, stroke, neurological disorders (Parkinson’s disease, epilepsy, 
neuropathy, myopathy, spinal disc herniation, multiple sclerosis), peripheral 
vascular disease, renal insufficiency, arthritis) was determined. Collected data 
were verified with records from the participant’s general physician and local 
pharmacist. Height and weight were measured using standardized equipment 
and procedure. Body mass index (BMI) was calculated as body weight divided 
by height squared (kg/m2).
biochemistry
Nonfasting blood samples were collected at the baseline assessment. Serum 
25(OH)D levels were measured using a radioimmunoassay (DiaSorin, Saluggia, 
Vercelli, Italy). Intra- and interassay coefficients of variation were less than 10%.
Classification of vitamin D status
Serum 25(OH)D groups were chosen based on levels of vitamin D deficiency as 
described in the literature(1,16): severe deficiency (<25.0 nmol/L), moderate de-
ficiency (25.0–49.9 nmol/L), sufficient (50.0—74.9 nmol/L), and optimal (≥75.0 
nmol/L).
physical performance
Physical performance was assessed using handgrip strength measurements, 
the Timed Up and Go (TUG) Test, the Five Time Sit to Stand (FTSS) Test, and the 
tandem stand test. Handgrip strength(17), was measured in kilograms using a 
digital strain-gauged dynamometer (Takei TKK 5401, Takei Scientific Instru-
ments Co., Ltd., Tokyo, Japan). Participants were asked to stand upright with 
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arms hanging beside their body; grip strength was measured in each hand. 
In the TUG Test(18), the time it took for participants to stand up from a sitting 
position, walk 3 meters along a line, perform a 180° turn, walk back to the chair, 
and sit down, as fast as safely possible, was measured. In the FTSS Test(19), the 
time it took participants to stand up and sit down five consecutive times, as fast 
as safely possible, was measured. Participants were not permitted to use their 
hands or the chair’s arm supports during standing up or sitting down. In the 
tandem stand test, participants stood fully independent for 10 seconds with 
one foot in front of the other. The test was scored as completed(1) or failed (0)(19). 
All tests were performed twice, and the best score was recorded.
statistical analysis
All analyses were performed using the SPSS version 17.0 (SPSS, Inc., Chicago, 
IL). Baseline characteristics were compared using Student t-test analyses for 
continuous variables and chi-square analyses for dichotomous variables. Linear 
regression and binary logistic regression models were constructed to adjust for 
potential confounders. The crude model was solely age adjusted. Potential con-
founders considered for inclusion in the multivariate model in addition to age 
were number of comorbidities, degree of urbanization, marital status, level of 
education, current or past smoker, alcohol units per day, MMSE score, and BMI. 
Confounders that led to a change in the regression coefficient (B) of 10% or more 
were retained in the multivariate-adjusted regression model. Participants with 
incomplete or missing performance test measures were excluded from related 
analyses (handgrip strength, n = 7; TUG Test, n = 55; FTSS Test, n = 95; tandem 
stand test, n = 4). Measures were missing mostly because of injuries after the 
fall (e.g., upper or lower extremity fractures) or preexisting conditions. Because 
of a right-skewed distribution, serum 25 (OH)D levels were log transformed 
(natural log) for the regression models, and a general linear model was used 
to multivariately compare all continuous outcomes and chi-square analyses to 
compare the tandem stand outcomes. All analyses were stratified according to 
sex, and P < .05 was considered statistically significant.
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results
Six hundred sixteen participants were enrolled in the IMPROveFALL study. In-
formation on serum 25(OH)D concentration was obtained from 600 participants 
(230 (38%) men; 370 (62%) women). The sex-specific baseline characteristics are 
shown in Table 1; the mean age was 76 ± 7.
The mean serum 25(OH)D concentration was 59 ± 29 nmol/L. Fifty-five 
participants (9%) had severe vitamin D deficiency (<25 nmol/L), 209 (35%) 
had moderate deficiency (25—49.9 nmol/L), 172 (29%) had sufficient vitamin 
D (50—74.9 nmol/L), and 164 (27%) had optimal 25(OH)D levels (≥75 nmol/L). 
One hundred two men (44%) and 162 women (44%) had serum 25(OH)D levels 
of less than 50 nmol/L.
Table 1. Baseline characteristics according to sex
Characteristic Men
(n=230)
Women
(n=370)
p-value
Age, mean ± SD 76.4 ± 6.7 76.5 ± 7.0 0.820
Serum 25(OH)D, mean ± SD 58.9 ± 30.9 58.7 ± 27.8 0.939
MMSE score, mean ± SD 27.0 ± 2.3 26.9 ± 2.4 0.716
Body mass index (kg/m2), mean ± SD 27.1 ± 3.9 27.9 ± 4.9 0.027
Secondary level of education, n (%) 185 (80) 250 (68) <0.001
Urban, n (%) 190 (83) 323 (87) 0.142
Recurrent fallers, n (%) 96 (42) 178 (48) 0.128
Smoking, n (%)
         Current 28 (12) 40 (11) 0.609
         Past 152 (66) 122 (33) <0.001
         Never 76 (33) 245 (66) <0.001
Alcohol units p/day, n (%) <0.001
         0  92 (40) 212 (57)
         <1 24 (10) 63 (17)
         1-3 66 (29) 78 (21)
          >3 48 (21) 17   (5)
Vitamin D supplements, n (%) 14   (6) 61 (17) <0.001
Number of comorbidities, mean ± SD 2.1 ± 1.2 2.1 ± 1.2 0.654
Number of medications, mean ± SD 5.9 ± 2.9 6.5 ± 3.5 0.027
Number of FRIDs, mean ± SD 2.5 ± 1.5 2.7 ± 1.6 0.378
FRID: fall-risk increasing drugs.
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Regression models of physical performance according to log-transformed 
serum 25(OH)D concentration were constructed (Table 2). In men, in the fully 
adjusted model, higher serum 25(OH)D concentrations were significantly asso-
ciated with better handgrip strength (B = 3.86, 95% CI = 2.04—5.69), faster TUG 
times (B = −2.82, 95% CI = −4.91 to −0.73), and faster FTSS times (B = −3.39, 95% 
CI = −5.67 to −1.11). In women, higher serum 25(OH)D concentrations were sig-
nificantly associated with faster TUG times (B = −2.68, 95% CI = −4.87 to −0.49).
A general linear model was used to compare the means of handgrip strength, 
TUG, and FTSS (Figure 1 A–C) according to sex and vitamin D group. In men, 
handgrip strength ranged from 30.3 kg (in participants with serum 25(OH)D 
levels <25 nmol/L) to 36.0 kg (in participants with 25(OH)D levels >75 nmol/L) 
(21.0 and 21.6 kg, respectively, for women). Results for the TUG Test ranged 
from 12.1 seconds (serum 25(OH) <25 nmol/L) to 9.9 seconds (serum 25(OH)
D) > 75 nmol/L) in men; results in women were 18.8 seconds and 12.0 seconds, 
respectively. Results for the FTSS Test ranged from 20.0 seconds (serum 25(OH) 
<25 nmol/L) to 14.6 seconds (serum 25(OH)D) > 75 nmol/L) in men; results in 
women were: 23.3 seconds and 17.9 seconds, respectively. The percentage of 
completed tandem stands according to vitamin D group was 68%, 59%, 64%, 
and 86%, respectively, in men (P = .009) and 44%, 61%, 66%, and 63%, respec-
tively, in women (P = .15).
Table 2. Results of regression analysis of strength and physical performance according to log transformed 
serum 25 (OH)D concentration and sex
Model 1 Model 2
Men (n = 230)
Handgrip strength (n=228) 4.02 [2.30; 5.75]*** 3.86 [2.04; 5.69]***
Timed “Up & Go” (n=211) -3.02 [-5.03; -1.02]** -2.82 [-4.91; -0.73]**
Five Time Sit to Stand (n=197) -3.11 [-5.27; -0.94]** -3.39 [-5.67; -1.11]**
Tandem stand (n=230) 0.59 [1.05; 3.11]* 0.55 [0.93; 3.19]
Women (n = 370)
Handgrip strength (n=365) 0.80 [-0.13; 1.72] 0.67 [-0.26; 1.61]
Timed “Up & Go” (n=334) -3.19 [-5.34; -1.04]** -2.68 [-4.87; -0.49]*
Five Time Sit to Stand (n=308) -2.69 [-4.90; -0.49]* -2.13 [-4.30; 0.04]
Tandem stand (n=366) 0.15 [0.77; 1.76] 0.04 [0.68; 1.59]
Data are shown as B with the 95% confidence interval between square brackets.
Model 1: adjusted for age. Model 2: adjusted for age, number of comorbidities, smoking, degree of urbanization, 
body mass index, and MMSE score. *p < 0.05; **p < 0.01; ***p < 0.001.
100 | Chapter 3.1
dIsCussIon
Serum 25(OH)D levels were significantly associated with physical performance 
in older fallers who visited a hospital ED after a fall. The population consisted of 
older men and women with a mean age of 76, many of whom were vitamin D 
deficient; an average of 44% had 25(OH)D levels less than 50 nmol/L, making it 
a good population in which to investigate the relationship between vitamin D 
and physical performance. 
In men, an association was found between serum 25(OH)D levels and hand-
grip strength, TUG time, and FTSS time. In women, there was an association 
only between serum 25(OH)D level and TUG time. Various studies have dem-
onstrated a relationship between vitamin D and physical performance(5-11,20,21). 
Although most of these studies were conducted in female-only populations(5-8), 
some studies that included men and women reported similar results(2,20). In 
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Figure 1. Strength and physical performance according to serum vitamin D group and sex. General linear 
model analysis of (A) handgrip strength, (B) Timed Up and Go Test, and (C) Five Time Sit to Stand test with 
mean and standard error. Adjusted for age, number of comorbidities, smoking, degree of urbanization, 
body mass index, and Mini Mental State Examination score
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addition, a 3-year follow-up study reported poorer physical performance and 
a greater decline in physical performance in older vitamin D–deficient men 
and women(9), but recent studies investigating men specifically have not found 
an association between vitamin D levels and physical performance(10, 11). Lack 
of an association in the previously mentioned studies may be because of the 
target population (young, healthy men) and the low prevalence of vitamin D 
deficiency. In the current study, older persons were included who visited the 
hospital after a fall, which can be a sign of possible neuromuscular dysfunction. 
Variations in baseline functional status and vitamin D status are thought to be 
important in explaining conflicting results in studies that examine the associa-
tion between vitamin D and muscle function(22). 
The different results found for men and women, especially in the FTSS, are 
not easily explained. It is unclear whether vitamin D deficiency affects men and 
women differently. There is some evidence, mostly from ex vivo and in vitro stud-
ies, that this is the case(23). Sex hormones are known to modulate the vitamin D 
endocrine system and influence calcium homeostasis. For example, estrogen is 
known to stimulate vitamin D receptor expression and 1α-hydroxylase activity, 
and testosterone is reported to stimulate intestinal calcium channel expression(23). 
The following limitations should be taken into account when interpreting the 
results of the current study. First, the cross-sectional design of the study limits the 
ability to infer a causal relationship between serum 25(OH)D levels and physical 
performance and does not exclude the possibility of reverse causality. Second, 
serum parathyroid hormone (PTH) levels were not determined. Vitamin D defi-
ciency leads to an increase in serum PTH, which increases bone turnover and bone 
loss and is related to a decrease in muscle strength(23). Third, the use of a MMSE 
score of less than 21 as an exclusion criterion could have resulted in the exclusion 
of the frailest persons. Fourth, information regarding mood or depression was 
not recorded. Mood disorders might affect vitamin D status and neuromuscular 
performance. A major strength of this study is the substantial proportion of vita-
min D–deficient participants included, which enabled physical performance to 
be analyzed in vitamin D–deficient and –sufficient men and women. 
In addition, it was striking to note how few of the older fallers were prescribed 
vitamin D supplements, especially the men; although an average of 44% of the 
men and women were deficient in vitamin D, only 6% of the men and 17% of the 
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women were taking vitamin D supplements. The underprescribing of vitamin 
D in this age group has been reported(24), but despite evidence that vitamin 
D supplementation has been shown to increase muscle strength and reduce 
the risk of falls(25), vitamin D deficiency is common in community-dwelling 
elderly adults, with a prevalence of 40% to 100% in U.S. and European older 
men and women(1). Furthermore, although the level for vitamin D sufficiency 
was set at 50 nmol/L or greater, another opinion is that vitamin D levels should 
be 75 nmol/L or greater(26). This is interesting to note when considering Figure 
1, which indicates that levels closer to 75 nmol/L result in physical performance 
benefits, especially in men.
In conclusion, higher serum 25(OH)D concentration was associated with bet-
ter strength and physical performance in older male and female fallers.
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Effect of high dose vitamin D 
supplementation on neuromuscular 
function in older vitamin D deficient 
individuals living in residential care: a 
double blind placebo controlled trial
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abstraCt
Background: Vitamin D deficiency is a prevalent condition among older indi-
viduals, and is associated with myopathy and a decrease in neuromuscular 
performance. 
Objective: To study the effects of a daily dose of 1800 IU vitamin D3 on muscle 
strength, gait speed and Timed Up and Go Test (TUGT) performance. 
Design: In this double-blind trial, subjects aged ≥ 65 years, living in residen-
tial homes, with serum 25-hydroxyvitamin D3 (25(OH)D3) concentrations < 50 
nmol/l were randomly assigned to receive either a daily dose of 1800 IU vitamin 
D3 (n = 124) or  placebo (n = 118). 
Endpoints: Change in quadriceps extension strength was the primary end-
point. Secondary endpoints included change in handgrip strength, 6 meter 
walking test performance and Timed Up and Go Test performance. 
Results: Serum 25(OH)D3 concentrations rose significantly (from 32.1 nmol/l 
to 107.3 nmol/l, P < 0.001) in participants treated with a daily dose of 1800 IU 
vitamin D3. An improvement in gait speed and TUGT performance was observed 
in the intervention group of respectively 6.0% and 4.8%. The improvement was 
most pronounced in the participants with baseline 25(OH)D3 levels of ≤ 25 
nmol/l. No effect on quadriceps strength or handgrip strength was observed. 
Conclusions: Daily treatment with 1800 IU vitamin D3 raised 25(OH)D3 con-
centrations in older, mild-moderate vitamin D–deficient individuals was associ-
ated with an improvement in gait speed and TUGT performance. Further studies 
with a longer follow up are needed to assess the additional benefit and safety 
of high dose supplementation. This trial is registered at Current Controlled Trials 
as ISRCTN33988275.
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IntroduCtIon
Vitamin D, a seco-steroid hormone, is mostly known because of its importance 
for calcium homeostasis and bone health. In recent years it has become clear 
that the vitamin D receptor (VDR) via which the vitamin D metabolites exert their 
function, is expressed by almost all cells in the human body, including skeletal 
muscle cells(1). Via the VDR, the vitamin D metabolites exert both genomic and 
non-genomic effects on muscle cells which are important for muscle function(2). 
Older people are at particular risk of developing a vitamin D deficiency because 
of a decreased cutaneous vitamin D production capacity, a decrease in time 
spent outdoors, and less dietary intake of vitamin D(3).
Key symptoms of vitamin D deficiency associated myopathy are proximal 
muscle weakness, muscle pain and gait disturbances(4). Observational studies 
have reported numerous associations between vitamin D status and neuro-
muscular function in older individuals. Intervention trials assessing the effect 
of vitamin D supplementation on neuromuscular performance have yielded 
inconsistent results(5, 6). Although various methodological causes can be consid-
ered, an important cause of several negative trial results could be that the dose 
of vitamin D supplementation used is too low, i.e. the obtained serum 25(OH)
D3 level after the intervention is too low. Large observational studies suggest 
that optimal 25(OH)D3 levels for neuromuscular performance could be as high 
as > 75 – 100 nmol/l, a level which is not reached in most intervention trials(7). 
Therefore we assessed the effect of high dose vitamin D supplementation (1800 
IU/day) on neuromuscular function in older people and hypothesized that high 
dose vitamin D supplementation has a more pronounced effect on muscle 
strength and mobility compared to low dose vitamin D supplementation. 
methods 
subjects
Participants were recruited from residential homes during the period March 
2008 – March 2010. Participants were eligible if age was ≥ 65 years, they were in 
stable health, they were able to perform (most of ) the neuromuscular tests and 
serum 25(OH)D3 level was < 50 nmol/l. Exclusion criteria were: renal insufficiency 
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(GFR < 40 ml/min), hypercalcaemia (serum calcium > 2.70 nmol/l), diagnosis of 
dementia or mini mental state examination score < 20 points, primary hyper-
parathyroidism, current malignant disease (any), history of renal stones and use 
of digoxin or anti-epileptic drugs (any). Participants were also excluded if they 
had a history of recurrent falls. The initial selection process was performed by 
the staff of the residential care facility, based on both the inclusion and exclu-
sion criteria, expected willingness to participate and chance of finalizing the 
follow up period. The protocol was approved by the Medical Ethics Committee 
of the Erasmus MC (MEC 2007-160) and written informed consent was obtained 
from all participants. 
study design
This 6-month randomized, double-blind, placebo-controlled, trail, to assess 
efficacy and safety of daily 1800 IU vitamin D3 in older vitamin D deficient 
individuals was conducted in residential homes in the western part of the 
Netherlands. The primary endpoint was change in quadriceps strength during 
the study period. Secondary endpoints included change in handgrip strength, 
gait speed and mean serum 25(OH)D3 level. Participants were randomized to 
receive either a daily dose of 1800 IU vitamin D3 (cholecalciferol) or a placebo. 
Trial medication consisted of two vials of 100ml each, with a vitamin D solution 
of 1800 IU/ml or matching placebo. Compliance was monitored by staff in the 
residential homes and documented. Adverse events (AEs) were recorded by the 
staff of the residential home at any time during the study.
baseline characteristics
Participants were selected based on medical history, current physical condition, 
and medication use including supplements. Information total morbidity was 
obtained from the nurses’ record of the residential home. Cognitive functioning 
was assessed using the Dutch version of the Mini-Mental State Examination 
(MMSE), with a score ranging from 0 points (poor cognitive functioning) to 30 
points (good cognitive functioning). 
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assessment of muscle strength and neuromuscular function
Four different tests were performed, namely: isometric quadriceps femoris 
muscle extension strength measurement, handgrip strength measurement, 
6-meter walking test and Timed Up and Go Test (TUGT) performance. For each 
test, it was first checked whether the patient knew how to perform the test 
properly; handgrip strength and quadriceps strength measurement were re-
hearsed one time. All tests were performed two times. The best score of the two 
measurements was used for the analysis. Maximal isometric quadriceps femoris 
muscle extension strength was measured preferably at the dominant side with 
the handheld MicroFET dynamometer (in Newton). During this measurement 
the dynamometer is placed just proximal to the ankle on the front lower leg (on 
the distal tibia and anterior tibial muscle tendon). The researcher then holds the 
dynamometer stationary while the participant exerts a maximal force against 
it; therefore the test is essentially isometric. Handgrip strength (in Kg) at the 
dominant side was measured using a portable Takei handheld dynamometer 
(Takei Scientific Instruments Co. Ltd, Tokyo, Japan). The 6-meter walking test 
measures the time (in seconds) that it takes a patient to walk 6 meters. It as-
sesses short-duration walking speed. The TUGT is a test for balance that is com-
monly used to examine functional mobility in older adults. The test requires a 
subject to stand up, walk 3 meter, turn, walk back, and sit down. The duration of 
this test is measured in seconds. All measurements were performed at baseline 
and after six months. In case participants completed taking the trial medication 
before the end of the 6 month follow up period, follow up measurements were 
performed earlier. 
Vitamin d measurement 
Laboratory measurements were performed at the Erasmus University Medi-
cal Center. In case of logistic problems measurement were performed by the 
local laboratory, affiliated with the particular residential care facility. In some 
cases, where serum 25OHD3 level measurement had been recently performed 
(< 1 month) by the general practitioner, this measurement was used as base-
line measurement (measurement also performed by local laboratory). In the 
Erasmus University Medical Center, serum 25(OH)D3 levels (in nmol/l) were 
measured using a radio-immuno-assay (DiaSorin, Stillwater, MN, USA). 
110 | Chapter 3.2
statistical methods
Before starting the study, we estimated that for our main study outcome regard-
ing the effect of vitamin D supplementation we would need 250 participants to 
have 80% power for a detection of an improvement of 7%, taking into account 
an alpha of 0.05. 
Population characteristics were reported as mean ± SD. Baseline differences 
between the two groups (intervention or placebo) were tested using an inde-
pendent t-test for normally distributed variables (age, gender and MMSE score) 
and the Mann–Whitney test for skewed variables (cal cium intake and serum 
25(OH)D3 level, MMSE score).
Within-group changes over the 6 month study period in the intervention 
and the placebo groups were compared using a t-test for paired observations. 
Statistical significance of the difference in change between the intervention 
and the placebo group were tested using an independent sample t-test. Data 
were analyzed on an intention to treat basis. Missing values were imputated by 
random sampling using the mean and standard deviation. 
All statistical analyses were performed using SPSS software (version 16.1.1; 
SPSS Inc., Chicago, Illinois). A p-value of < 0.05 was considered statistically 
significant.
results
In this prospective, randomized, double-blind, placebo controlled trial, 409 sub-
jects who fulfilled the inclusion criteria were screened for vitamin D deficiency 
(Figure 1). Of those, 242 were randomized to receive either vitamin D supple-
mentation or placebo. The main reasons for exclusion were memory complaints 
or a too low MMSE score, and withdrawal of informed consent.  
The characteristics of the study participants are shown in Table 1. The mean 
age of the study participants was 81.2 ± 6.9 years with a mean serum 25(OH)
D3 level of 32.5 ± 7.7 nmol/l. At baseline there were no differences between the 
two treatment groups. During the study period, 3 participants died and 16 were 
lost to follow up. Tolerability of the trial medication was good; no specific drug 
related complaints were reported.  
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Figure 1 Study flowchart
Table 1 Baseline characteristics of the study participants
Characteristic Vitamin D3
(n = 124)
Placebo
(n = 118)
P value
Age, yr 81.5 ± 7.0 80.6 ± 6.7 p = 0.32
Female, n (%) 94 (76%) 85 (72%) P = 0.51
MMSE score (points) 26.8± 2.5 26.4 ± 2.6 p = 0.30
Serum 25(OH)D3 (nmol/l) 32.1 ± 8.5 33.3 ± 7.1 p = 0.21
Serum calcium (mmol/l) 2.28 ± 0.10 2.26 ± 0.11 p = 0.16
Serum creatinine (µmol/l)  75.8 ± 12.1 73.1 ± 12.5 p = 0.09
Quadriceps extension strength (N) 163.1 ± 29.5 166.9 ± 29.4 p = 0.31
Handgrip strength (Kg) 23.8 ± 4.0 24.1 ± 4.2 p = 0.30
6m walking test (s) 6.7 ± 1.5 6.5 ± 1.5 p = 0.43
Timed Up and Go Test (s) 12.5 ± 2.4 12.2 ± 2.2 P = 0.40
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effects on vitamin d status and serum calcium levels
The dose of vitamin D was effective in increasing mean 25(OH)D3 levels at 6 
months compared with placebo. During the study period mean 25(OH)D3 level 
in the placebo group increased from 33.3 to 34.5 nmol/l (3.6% increase; p = 
0.06). In the active treatment group, mean 25(OH)D3 levels increased from 32.1 
to 107.3 nmol/l (234.1 % increase; p < 0.001). 
effect on muscle strength
Table 2 shows the changes in muscle strength for the intervention and placebo 
group. Overall quadriceps strength in the intervention group improved from 
163N to 165N (p > 0.05). No association was seen with baseline serum 25(OH)D3 
level. In the placebo group, also significant change was seen in muscle strength. 
Mean handgrip strength in the intervention group increased from 23.8 Kg to 
24.2 Kg (p > 0.05). Again, no association was seen with baseline serum 25(OH)
D3 level. Also, in the placebo group, no significant change was seen in handgrip 
strength. For both quadriceps strength and handgrip strength no association 
correlation was seen between change in vitamin D status and change in vitamin 
D status during the intervention (p >0.05)
Table 2 Change in muscle strength 
Vitamin D (n = 124) Placebo (n = 118)
Test Baseline Follow Up %
change
Baseline Follow up %
change
Quadriceps strength (N)
Overall (n = 124) 163.1 ± 29.5 165.4 ± 30.8 1.4% (n =118) 166.9 ± 29.4 167.7 ± 29.2 0.5%
s-25(OH)D3 ≤ 25 (n = 31) 156.6 ± 28.4 158.5 ± 28.6 1.2% (n=15) 161.7 ± 25.9 160.6 ± 24.0 - 0.7%
s-25(OH)D3 > 25 (n = 93) 165.2  ± 29.7 167.8 ± 31.4 1.6% (n = 103) 167.6 ± 29.9 168.7 ± 29.8 0.6%
Handgrip strength (Kg)
Overall (n = 124) 23.8 ± 4.0 24.2 ± 4.1 1.7% (n = 118) 24.1 ± 4.2 24.3 ± 3.9 0.8%
s-25(OH)D3 ≤ 25 (n = 31) 23.1 ± 4.1 23.8 ± 4.5 3.0% (n=15) 23.1 ± 3.8 23.2 ± 3.9 0.4%
s-25(OH)D3 > 25 (n = 93) 24.0 ± 3.9 24.3 ± 4.0 1.3% (n = 103) 24.3 ± 4.3 24.4 ± 3.9 0.4%
* t-test for paired observations, significantly different from baseline, P < .05  
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effect on neuromuscular performance
Table 3 shows the changes in neuromuscular test performance for the inter-
vention and placebo group. In the intervention group there was a significant 
improvement in gait speed. Mean 6 meter walking time decreased from 6.7 
seconds (equals 0.90 m/s) to 6.3 seconds (equals 0.95 m/s, 6.0% improvement; 
p < 0.05). In participants with baseline 25(OH)D3 levels of ≤ 25 nmol/l, 6 meter 
walking time improved 8.3% versus 4.6% in participants with serum 25(OH)
D3 levels > 25 nmol/l (p < 0.05). No significant change was seen in gait speed 
in the placebo group. TUGT performance in the intervention group improved 
with 4.8%. The improvement in participants with a baseline serum 25(OH)D3 
level of ≤ 25 nmol/l was 7.7% (p < 0.05). The improvement in participants with 
a baseline 25(OH)D3 level > 25 nmol/l was 3.4% (p > 0.05).  For both 6 meter 
walking test and TUGT, no correlation was observed between change in test 
performance and change in vitamin D status during the intervention (p > 0.05).
dIsCussIon
In the present study, performed in older, vitamin D deficient individuals, liv-
ing in residential care, treatment with high dose cholecalciferol for 6 months 
improved both gait speed and TUGT performance. Improvement was most 
pronounced in participants with baseline serum 25(OH)D3 levels ≤ 25 nmol/l. 
Table 3 Change in gait speed and Timed Up and Go Test (TUGT) performance
Vitamin D (n = 124) Placebo (n = 118)
Test Baseline Follow Up %
Change
Baseline Follow up %
Change
Gait speed (s)
Overall (n = 124) 6.7 ± 1.5
(0.90 m/s)
6.3 ± 1.3
(0.95 m/s)
- 6.0%* (n =118) 6.5 ± 1.5
(0.92 m/s)
6.7 ± 1.4
(0.90 m/s)
3.1%
s-25(OH)D3 ≤ 25 (n = 31) 7.2 ± 1.5 6.6 ± 1.2 - 8.3%* (n=15) 7.5 ± 1.6 7.4 ± 1.3 - 1.3%
s-25(OH)D3 > 25 (n = 93) 6.5 ± 1.4 6.2 ± 1.3 - 4.6%* (n = 103) 6.4 ± 1.5 6.5 ± 1.4 1.6%
TUGT (s)
Overall (n = 124) 12.5 ± 2.4 11.9 ± 2.4 - 4.8%* (n =118) 12.2 ± 2.2 12.4 ± 2.2 1.6%
s-25(OH)D3 ≤ 25 (n = 31) 13.0 ± 2.3 12.0 ± 2.0 - 7.7%* (n=15) 12.6 ± 2.1 12.9 ± 2.0 2.4%
s-25(OH)D3 > 25 (n = 93) 12.3 ± 2.4 11.9 ± 2.5 - 3.4% (n = 103) 12.2 ± 2.3 12.3 ± 2.2 0.8%
* t-test for paired observations, significantly different from baseline, P < .05  
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No effect of vitamin D supplementation was observed on quadriceps extension 
strength and handgrip strength. 
A daily dose of 1800 IU vitamin D3 was effective in raising the mean serum 
25(OH)D3 concentration from a mean of 32.1 to 107.3 nmol/l in the intervention 
group. In the placebo group, serum 25OHD3 levels did not change significantly, 
suggesting marginal seasonal influences on vitamin D status in this cohort. The 
high dose vitamin D supplementation was well tolerated in this cohort of older 
people and no adverse events were reported. 
The results of the present study support the hypothesis that vitamin D is 
important for muscle function, and the results suggest that a state of vitamin 
D deficient myopathy is potentially reversible with vitamin D supplementa-
tion. Previous studies showed variable results regarding the effect of vitamin 
D supplementation on muscle strength and neuromuscular performance. In 
this study, no effect of high dose vitamin D supplementation was observed on 
either quadriceps strength and handgrip strength. These findings contrast with 
some previous results that did report an effect on muscle strength. For example, 
a previous study in frail older women showed that a supplementation dose of 
1000 IU ergocalciferol for 2 years resulted in an increase of quadriceps strength 
of almost 50%(8). In two other studies vitamin D supplementation resulted in a 
4% to 11% improvement in lower extremity strength or function. On the other 
hand for example, studies by Brunner et al. and Dhesi et al., failed to find an 
effect of vitamin D supplementation on muscle strength(9, 10). Possible causes 
of these variable study results are thought to be variation in supplementation 
duration and dose, variation in participant age and co-morbidities. In addition, 
a recent meta-analysis suggested that severity of vitamin D deficiency could be 
important. This study concluded that vitamin D supplementation does not have 
a significant effect on muscle strength in adults with baseline 25OHD3 levels > 
25 nmol/l(11).  
With regard to the effect of vitamin D supplementation on gait speed, the 
observed trial results in the literature are also variable. In this study an overall 
improvement in gait speed of 6.0% was observed, and this improvement was 
8.3% in participants with baseline 25OHD3 levels < 25 nmol/l versus 4.3% in 
participants with baseline levels > 25 nmol/l. Parallel to our findings, a study 
by Bunout et al., reported an improvement of gait speed with a vitamin D 
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supplementation dose of 400IU/day and 800mg of calcium/day for 9 months(12). 
These findings contrast several other studies that found no effect of vitamin D 
supplementation on gait speed(10, 13, 14). Again, these studies varied strongly in 
supplementation dose, study population and trial duration. In a recent meta-
analyses by Muir et al., an effect on gait speed was not found. This study con-
cluded that most trials had methodological issues that limited comparability, 
and further research was recommended(15). A recent study by Bischoff-Ferrari 
et al., examining the effect of vitamin D supplementation on gait speed, dem-
onstrated a superior effect of calcifediol versus cholecalciferol on gait speed. 
In this study, women receiving calcifediol had an 18% greater improvement in 
gait speed at 4 months follow up, compared to women receiving cholecalciferol 
supplementation(16). 
In the present trial, high dose vitamin D supplementation was used, which 
resulted in a mean serum 25OHD3 level of 107 nmol/l in the intervention group. 
No correlation however was observed between change in serum 25(OH)D3 level 
and improvement in neuromuscular function or muscle strength; i.e. a greater 
improvement in vitamin D status did not result in a greater improvement in 
test performance. This raises the question what the ideal supplementation dose 
or serum 25OHD3 level is, and if high dose supplementation is truly beneficial. 
Furthermore, the observed improvement in this trial, when compared to 
other positive trials, that used lower dose supplementation, is not superior(17). 
Furthermore, in regard to the observed improvement in gait speed, the clini-
cal relevance is unclear. The mean observed improvement was 0.05m/s, while 
generally a change of at least 0.1 m/s in gait speed is considered a substantial 
meaningful change(18, 19). The issue of defining the optimal serum 25OHD3 level 
is relevant because, while no adverse effects were observed in this relatively 
short trial, some observational studies on cardiovascular endpoints reported 
an U-shaped risk profile between cardiovascular risk and serum 25(OH)D3 lev-
els(20-22). The nadir in most of these studies with regard to the cardiovascular risk 
or survival was about 60 nmol/l. An increase in fall and fracture risk with high 
dose vitamin D supplementation has also been reported(23, 24).
This trial has several strengths. Given the fact that medication was ad-
ministered by the staff of the residential care facilities, compliance was well 
documented. Furthermore, loss to follow up in this trial was limited. However, 
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several limitations have to be considered. First, given the fact that this trial was 
performed in residential care facilities, results can not readily be extrapolated to 
community dwelling older persons. Second, in this trial we used a liquid vitamin 
D supplement. This may have resulted in dosing problems and some variation 
in daily dose. Many participants finished the vials of trial medication before the 
intervention period of 6 months had passed, which presumably resulted in a 
higher net intervention dose than 1800 IU/day. Third, serum 25OHD3 measure-
ments were performed in various laboratories while it is known that measure-
ment results vary between laboratories and methods. However, given the fact 
that this occurred in both the intervention and the control group, it is not likely 
that this affected the outcome of this trial. Fourth, no information was available 
on body mass index (BMI) while it is known that 25(OH)D3 levels are affected by 
BMI given the fact that it is a fat soluble hormone.
In conclusion, high dose vitamin D supplementation improved gait speed 
and TUGT performance in older persons living in residential care. No effect was 
observed on muscle strength. Future well designed studies with longer follow 
up periods are needed to further assess the effect of vitamin D supplementation 
on skeletal muscle function, and to define the optimal serum 25OHD3 level for 
muscle function.
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Higher serum vitamin D3 levels are 
associated with better cognitive 
test performance in patients with 
Alzheimer’s disease
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abstraCt
Background/Aims: Recent studies suggest that vitamin D metabolites may be 
important for preserving cognitive function via specific neuroprotective effects. 
No large studies have examined the association between vitamin D status and 
cognition. 
Methods: In this cross-sectional study, we analyzed the serum 25-hydroxyvi-
tamin D3 levels and Mini-Mental State Examination (MMSE) test scores of 225 
older outpatients who were diagnosed as having probable Alzheimer’s disease 
(AD). In addition to the 25-hydroxyvitamin D3 levels, we analyzed the serum 
vitamin B1, B6 and B12 levels.
Results: An association was found between MMSE test scores and serum 
25-hydroxyvitamin D3 levels, with β-coefficient of 0.05 (p = 0.01). Vitamin-D-suf-
ficient patients had significantly higher MMSE scores as compared to vitamin-D 
insufficient ones. No association was found with the other serum vitamin levels. 
Conclusions: These data support the idea that a relationship exists between 
vitamin D status and cognition in patients with probable AD. However, given 
the cross-sectional design of this study, no causality can be concluded. Further 
prospective studies are needed to specify the contribution of vitamin D status 
to the onset and course of cognitive decline and AD.
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IntroduCtIon
Dementia is associated with a higher rate of comorbidity, poor functional status 
and increased mortality(1–3). The emotional and financial burden of dementia 
and Alzheimer’s disease (AD) on society will increase in the next decades(4). 
The clinical assessment of dementia in specialized centers, such as memory 
clinics, has led to earlier diagnosis and has stimulated the search for potential 
therapeutic agents and preventative strategies(5). The American Academy of 
Neurology recommends screening for vitamin B12 deficiency and hypothyroid-
ism in patients with dementia(6). In the Dutch consensus, screening for folate 
and vitamin B1 , B6 and B12 deficiency is recommended
(7). 
Recent insights suggest that vitamin D, mostly known for its effects on cal-
cium and bone metabolism, may have neuroprotective functions and could be 
important for preserving cognitive functions via several different mechanisms(8). 
Vitamin D is a secosteroid hormone. The term vitamin D refers to the inert 
precursors vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). The pre-
cursors are either formed in the skin after exposure to sunlight or derived from 
dietary sources. In the liver, the precursors are converted to 25-hydroxyvitamin 
D3 [25-(OH)D3]. In the kidney, 25-(OH)D3 is hydroxylated to 1,25-dihydroxyvi-
tamin D3 [1,25(OH)2D3], the most active vitamin D metabolite 
(9). The serum 
25-(OH)D3 levels are generally used to determine the vitamin D status of an indi-
vidual. Serum 25-(OH)D3 levels of ≥ 50 nmol/l are generally defined as sufficient, 
although recent reports suggest that a serum 25-(OH)D3 level ≥ 75 nmol/l may 
be preferable for optimal health(10). 
The vitamin D metabolites exert their effects via the vitamin D receptor (VDR). 
Recently, it has been shown that neurons also express the VDR, which makes 
them a potential target tissue for vitamin D metabolites(11). The VDR is abun-
dantly expressed in regions frequently affected in AD such as the hypothala-
mus, substantia nigra, cortex and hippocampus. The importance of a sufficient 
vitamin D status for cognitive functioning in humans is not known. A recent 
study reported an association between serum 25-(OH)D3 levels and cognitive 
functioning in a relatively small cohort of patients referred to a memory clinic(12). 
Because of these new insights, we examined the relationship between vita-
min D status and cognitive function in a cohort of older patients with probable 
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AD in our memory clinic. We also analyzed the serum levels of vitamin B1 , B6 
and B12 , as screening for deficiencies in these vitamins is recommended in the 
clinical guidelines for the assessment of dementia.
methods
patients
We included 962 consecutive patients who were referred to the geriatric outpa-
tient clinic of the Erasmus University Medical Center. The patients were referred 
for a variety of reasons and underwent a comprehensive geriatric assessment, 
including history and informant history, medication history, and physical and 
neurological examination(13). They were asked to complete the Dutch version of 
the Mini-Mental State Examination (MMSE), with scores ranging from 0 points 
(poor cognitive functioning) to 30 points (good cognitive functioning) (14). A 
consensus diagnosis of probable AD was obtained for 350 patients by a multi-
disciplinary memory clinic team including 2 geriatricians, a neurologist, a neu-
ropsychologist and a psychiatrist(15). Seventy-seven percent also underwent a 
neuropsychological examination. After exclusion of patients taking any vitamin 
suppletion at the time of investigation, serum vitamin B1 , B6, B12 and 25-(OH)
D3 levels were available for 225 out of 350 patients. The study was approved by 
the medical ethics committee of the Erasmus University Medical Center. Oral 
informed consent was obtained from the patients and their main caregiver.
dementia diagnosis
The diagnosis of dementia was verified according to a standard protocol. De-
mentia was diagnosed with reference to the American Psychiatric Association’s 
criteria (DSM-IV) 16). The subdiagnosis of probable AD was based on the criteria 
of the NINCDS-ADRDA work group(17).
possible cofactors
The serum 25-(OH)D3 level strongly depends on sunlight exposure and therefore 
data were collected on action radius and mobility as indicators for exposure to 
sunlight. The action  radius was classified as going outside, being housebound 
or lying in bed > 20h per day. For scoring mobility we used a standardized mo-
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bility scale assessing independence in walking, standing, transfers in and out of 
bed/chair, and wheelchair use. The score for each of these items ranged from 
0 points (complete independence) to 3 or 4 points (complete dependence), 
with a maximum score of 14 points(18). The total years of education were scored 
because both cognitive test performance and serum 25-(OH)D3 level are influ-
enced by educational background(19).
blood parameters
Blood samples were collected on the first visit to the outpatient clinic. The se-
rum 25-(OH)D3 levels were measured using a radioimmunoassay (DiaSorin). The 
serum vitamin B1 and B6 levels were determined by high-performance liquid 
chromatography according to internal protocols of the clinical laboratory of the 
Erasmus University Medical Center. The serum vitamin B12 levels were measured 
using a competitive protein-binding assay according to internal protocols of 
the clinical laboratory of the Erasmus University Medical Center. All assessments 
were performed at the Erasmus University Medical Center.
statistical analysis
The association between serum vitamin levels [25-(OH)D3, vitamin B1, B6 and 
B12] and MMSE score (dependent variable) was investigated by linear regres-
sion. To adjust for possible confounders, the models were adjusted for biologi-
cally plausible cofactors. These cofactors were age, gender, total mobility score, 
action radius, years of education and the vitamin levels not under investigation. 
They were added to the model one by one as linear covariables. Furthermore, 
the mean MMSE scores were compared between vitamin-D-insufficient and 
vitamin-D-replete patients. The cutoff point for defining vitamin D deficiency 
was set at a serum 25-(OH)D3 level < 50 nmol/l
(20). SPSS version 12.0 was used 
for statistical analysis (SPSS Inc., Chicago Ill., USA).
results
The characteristics of the population are shown in Table 1. The mean MMSE score 
was 19.7 ± 6.3 points and the mean serum 25-(OH)D3 level was 45.4 ± 22.8 nmol/l. 
In this cohort 141 out of 225 individuals (63%) had a serum 25-(OH)D3 level < 50 
nmol/l and 197 out of 225 (88%) had serum 25-(OH)D 3 levels < 75 nmol/l.
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The results of the regression analysis studying the association between 
serum 25-(OH)D3 levels and MMSE scores are shown in Table 2. A positive as-
sociation between serum 25-(OH)D3 levels and MMSE score was observed with 
a β-coefficient of 0.08 (p < 0.001). This finding remained significant after adjust-
ment for possible confounders ( β = 0.05; p = 0.01). The mean MMSE score in 
vitamin D-deficient patients [25-(OH)D3 < 50 nmol/l] was 18.5 ± 6.0 points and 
that in vitamin-D-replete patients was 21.5 ± 6.1 points (p = 0.003). Figure 1 
shows a scatter plot of the MMSE score versus serum 25-(OH)D3 level. Both in 
the adjusted and unadjusted models no significant associations were observed 
between serum vitamin B1, B6 and B12 levels and MMSE score (Table 2).
Table1. Characteristics of study population (N = 225)
Characteristics Mean ± SD Range
Age (years) 77,6 ± 7,3 60 - 94
Gender: female, no. (%) 147 (65%) -
MMSE score (points) 19,7 ± 6,3 1 - 30
Mobility score (points) 1,3 ± 2,8 0 - 14
Education (years) 8,8 ± 3,1 3 – 20
s-25(OHD3, nmol/l
    (normal range > 50)
45,4 ± 22,8 5 - 106
s-vitaminB1, nmol/l
    (normal range: 70-140)
105,1 ± 26,3 47 – 167
s-vitamin B6, nmol/l
    (normal range: 46-126)
63,3 ± 44,5 26 – 151
s-vitamin B12, pmol/l
   (normal range: 145-637)
304,5 ± 137,7 60 - 755
SD = standard deviation
Table 2. Linear regression (β) coefficients describing the association between MMSE score (dependent 
variable) and serum vitamin levels  
AD subgroup
(N = 225)
Unadjusted 
β coefficient
P value Adjusted 
β coefficient
P value
s-25(OH)D3 level 0,08 < 0,001 0,05 0,01
s-vitamin B1 level 0,03 0,1 0,02 0,3
s-vitamin B6 level 0,003 0,8 0,005 0,6
s-vitamin B12 level -0,001 0,9 -0,002 0,5
Adjusted: age, sex, mobility score, action radius, total years of education and s-vitamin levels not under 
investigation 
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dIsCussIon
In the present study, performed in a geriatric outpatient population, we tested 
the hypothesis that the serum 25-(OH)D3 levels are related to the level of cogni-
tive functioning in patients with probable AD. We found an association between 
MMSE scores and serum 25-(OH)D3 levels. No link was observed between MMSE 
scores and serum vitamin B1, B6 or B12 levels. This may be due to the fact that the 
mean serum vitamin B1, B6 and B12  levels were within the normal range. 
The high prevalence of vitamin D deficiency in our patients is in accordance 
with other reports both from the Netherlands and abroad(21,22). 
Our study is, to the best of our knowledge, the largest to date examining the 
association between serum 25-(OH)D3 level and cognition in a cohort of older 
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Figure 1 Scatter plot of the MMSE score (x-axis) versus s-25OHD3 level (y-axis)
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AD patients. The results are in line with a previous study on the association 
between serum 25-(OH)D3 levels and cognitive functioning
(12). 
Given the cross-sectional design of this study, the association between 
vitamin D status and MMSE scores can be interpreted in several ways. First, 
vitamin D deficiency may lead to a gradual decline in cognitive functions. Data, 
mostly from ex vivo and animal studies, suggest that vitamin D metabolites may 
have protective effects on neurons or neurotransmitter pathways which could 
benefit cognition. It has been proposed that vitamin D metabolites exert their 
protective effects on the central nervous system by stimulating the production 
of neurotrophins or by inhibiting the production of inducible nitric oxide(8). 
A positive effect of 1,25-(OH)2D3 on the acetylcholine pathway has also been 
reported(23). Recent studies suggest that 1,25-(OH)2D3 may also decrease the 
production of pro-inflammatory cytokines like tumor necrosis factor α. Tumor 
necrosis factor α is thought to play a pathogenic role in neurodegenerative 
disorders, such as AD and Parkinson’s disease(24, 25). 
Conversely, cognitive decline may cause vitamin D deficiency. It has been 
shown that AD can lead to malnutrition, which in turn could contribute to the 
development of vitamin D deficiency(26). In addition, exposure to sunlight might 
decrease due to behavioral problems in AD, such as apathy and inertia, leading 
to more time being spent indoors(27). 
A reduction in VDR expression in different layers of the hippocampus in 
patients with AD has been reported(28). The hippocampus is the most typical 
part of the brain involved in AD. The regulators of VDR expression in the central 
nervous system are still largely unknown. In other cell types such as muscle 
cells, a decreased expression of the VDR, independent of serum vitamin D level, 
has been described with aging(29). However, contradictory results, which ques-
tion the role of vitamin D metabolites in the preservation of cognitive function, 
come from a recent animal study that showed muscular and motor impairments, 
but no impairments in cognition, in VDR knockout mice compared to wild-type 
mice(30). 
Our study has some limitations. First, because of the cross-sectional design, no 
causality can be concluded. However, it seems worthwhile to gain more insight 
into the association between vitamin D deficiency and cognitive impairment, as 
supplementation of vitamin D might be an inexpensive and safe intervention(31). 
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Second, the MMSE is a crude measure of cognitive functions and fluctuations 
in cognition could have been missed(32). However, AD diagnosis in our patients 
was verified by neuropsychological testing and based on a thorough multidisci-
plinary diagnostic process. In view of the high prevalence of vitamin D deficiency 
in our rather mobile outpatients, our study supports the recommendations for 
preventative vitamin D supplementation in older people at risk(22). 
In conclusion, the results of the present study suggest that an association 
exists between vitamin D status and cognitive functioning in AD. Further pro-
spective studies with a long follow-up period and with more elaborate data 
on cognitive function and cognitive test performance are needed to specify 
the possible contribution of vitamin D deficiency to the onset and course of 
cognitive decline and AD. In the meantime, we should continue to recognize 
that vitamin D deficiency is prevalent in older persons. Quite apart from the 
consideration that vitamin D metabolites may have specific neuroprotective ef-
fects, the need to identify and treat comorbid conditions in AD patients remains 
unchanged(33).
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abstraCt
Aim: In this study we investigated the association between serum vitamin D 
levels in relation to carotid and radial artery distensibility.
Methods: Older men and women referred to the outpatient clinic of the de-
partment of internal
medicine and geriatric medicine were asked to participate in this cross sec-
tional study. Carotid and radial artery distensibility coefficients were measured. 
Linear regression analyses were performed to investigate the association be-
tween serum 25(OH)D levels and carotid and radial distensibility.
Results: The mean age of this population was 77.9 years and 28/49 (57%) were 
women. The mean serum 25(OH)D level was 50±28.8nmol/L. Serum 25(OH)D 
level was associated with carotid artery distensibility (β = 0.067; 95% CI, 0.021, 
0.113). No association was observed with radial artery distensibility (β = 0.015; 
95% CI, -0.031, 0.061). An association was also observed between serum 25(OH)
D level and carotid artery intima-media thickness (β = -0.002; 95% CI, -0.004, 
0.00).
Conclusion: In this cohort of older men and women serum 25(OH)D levels 
were associated with both structural and functional properties of the carotid 
artery. No association was observed with the radial artery distensibility.
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IntroduCtIon
Vitamin D, a seco-steroid hormone, is mostly known because of its importance 
for calcium homeostasis and bone health. Vitamin D is obtained through cuta-
neous synthesis resulting from sun exposure, and through oral intake from food 
and supplement sources(1). In recent years it has become clear that the vitamin 
D receptor (VDR) via which the vitamin D metabolites exert their function, is 
expressed by almost all cells in the human body(2). Vitamin D deficiency, as as-
sessed by circulating 25-hydroxyvitamin D3 (25(OH)D) levels, has in recent years 
drawn attention as a potential risk factor for cardiovascular disease (CVD)(3). 
Vitamin D deficiency is thought to influence CVD risk predominantly by acting 
on established CVD risk factors, such as hypertension, insulin resistance, and 
inflammation(4). Recent publications suggest that vitamin D deficiency is also 
associated with and increased risk of aortic stiffness(5, 6). 
Previously, we found that central and peripheral arteries can be affected differ-
ently in regards to structural and functional properties(7). In addition, if vascular 
stiffening (i.e. a decrease in vascular distensibility) is associated with vitamin D 
status and if there is a difference between various vascular regions is still unclear. 
The aim of this study is to assess whether mean serum 25(OH)D levels are associ-
ated with structural and functional arterial properties in a cohort of older persons. 
methods 
study population
Consecutive patients referred to the outpatient clinic of the Department of 
Internal Medicine and Geriatric Medicine, of the Erasmus Medical Center, were 
asked to participate in the study. Patients with a cardiovascular event within 6 
weeks before the visit were excluded from the study. Patients aged 55 years and 
older were included. Informed consent was obtained from all patients.
Cardiovascular risk Factors
Information on previous cardiovascular disease, smoking habits, and drug use 
was obtained by interview. Patients were classified as ever-smokers (current or 
past smokers) or never-smokers. Patients’ height and weight were measured, 
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and body mass index (BMI; weight [kg]/height2[m]) was calculated. Diabetes 
mellitus was defined as the use of blood glucose–lowering medication or a fast-
ing serum glucose level equal to or greater than 7.0 mmol/L.
blood pressure measurements
Blood pressure and heart rate were measured twice on the right arm using 
an automatic device (Accutorr Plus; Datascope Corporation, Mahwah, New 
Jersey). The measurements were obtained after at least 5 minutes of rest with 
the patient in the supine position. The pulse pressure (PP) was calculated as 
systolic blood pressure (SBP) - diastolic blood pressure (DBP).  The average of 
the 2 measurements was used in the analysis. 
arterial distensibility measurements
After at least 5 minutes of rest with the patient in the supine position, arterial 
measurements were performed by Wall Track System 2 (Pie Medical, Maastricht, 
the Netherlands), using a B-mode ultrasound to identify the right common ca-
rotid artery at 1 to 2 cm proximal to the origin of the bulb. The right radial artery 
was investigated at the antecubital crease. The end-diastolic diameter (D), the 
absolute stroke change in diameter during systole (ΔD), and the relative stroke 
change in diameter (ΔD/D) were computed as the mean of values measured in 4 
seconds of 3 successive recordings. The distensibility coefficient (DC) was calcu-
lated by the following equation: 2(ΔD/D)/PP (10 MPa−1). The means of diameter 
and distension of 3 successive recordings were taken as the subject’s readings.
Carotid artery intima-media thickness measurement 
The maximum common carotid intima-media thickness (IMT) was determined 
as the average of the maximum IMT of near- and far-wall measurements over a 
length of 1 cm, and the average of left and right maximum common carotid IMT 
was computed. 
measurement serum vitamin d levels
Blood samples were collected the same day as the cardiovascular measure-
ments were performed. The measurements were taken during a short period of 
time, from April until July. Serum 25(OH)D levels were measured using a radio-
immunoassay (DiaSorin).
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statistics
Mean values with standard deviation and percentages were calculated for con-
tinuous and categorical variables respectively. The association between serum 
25(OH)D levels and the various cardiovascular parameters (dependent vari-
able) was investigated by linear regression. Models were adjusted for possible 
confounders (age, gender, MAP, use of anti-hypertensives and heart rate). All 
analyses were performed using Statistical Package for the Social Sciences (SPSS) 
software (version 21.0). A p-value <0.05 was considered statistically significant. 
results
The characteristics of the study population are shown in Table 1. The mean sys-
tolic blood pressure was 130±15.5mmHg, and the mean diastolic blood pressure 
was 71 ± 9.1mmHg. The mean serum 25(OH)D level was 50 ± 28.8nmol/L. In this 
cohort 28 out of 49 participants (57%) had serum 25(OH)D levels ≤ 50nmol/L 
and 39 out of 49 (80%) had serum 25(OH)D levels ≤ 75nmol/L. 
The results of the regression analysis studying the association between serum 
25(OH)D levels and carotid and radial distensibility are shown in Table 2 and Fig-
Table 1 Baseline characteristics of the study participants
Characteristic Mean ± SD
 (N= 49)
Age, years 77,9 ± 7,8
Female, n (%) 28 (57%)
Smokers, % 9 (18%)
Anti-hypertensive therapy, % 20 (41%)
Diabetes mellitus, % 3 (6%)
Vitamin D supplement use, % 8/49 (16%)
Serum 25(OH)D (nmol/L) 50,3 ± 28,8
BMI, Kg/m2 25,6 ± 5,4
SBP, mmHg 130,8 ± 15,5
DBP, mmHg 71,1 ± 9,0
PP, mmHg 59,7 ± 11,4
MAP, mmHg 94 ± 11,8
IMT, mm 1,1 ± 0,6
Carotid distensibility, 10−3/kPa 11,0 ± 5,2
Radial distensibility, 10−3/kPa 7,5 ± 4,1
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure, PP = pulse pressure; IMT = 
carotid artery intima-media thickness; MAP = mean arterial pressure
138 | Chapter 4.1
ure 1. After adjustment for possible confounders a signifi cant association was 
observed between serum 25(OH)D levels and carotid distensibility (β = 0.067; 
95% CI, 0.021, 0.113). No association between serum 25(OH)D level and radial 
distensibility was observed (β = 0.015; 95% CI, -0.031, 0.061). Furthermore, a 
positive association was observed between serum 25(OH)D level and carotid 
artery IMT (β = -0.002; 95% CI, -0.004, 0.00). No association observed between 
serum 25(OH)D levels and either pulse pressure, SBP or DBP (Table 2).
Table 2 Linear regression β-coeffi  cients  and 95% Confi dence Interval (95% CI) describing the association 
between serum 25(OH)D levels and various vascular properties 
Characteristic β coeffi  cienta 95% CI
Carotid distensibility 0.067 0.021, 0.113
Radial distensibility 0.015 -0.031, 0.061
Systolic blood pressure -0.026 -0.090, 0.037
Diastolic blood pressure 0.034 -0.009, 0.077
Pulse pressure -0.060 -0.157, 0.037
Intima-media thickness -0.002 -0.004, 0.000
aModel adjusted for age, gender, Mean arterial Pressure, anti-hypertensive therapy and heart rate
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dIsCussIon
In the present study performed in older men and women referred to the outpa-
tient clinic, serum 25(OH)D levels were associated with both carotid distensibil-
ity and carotid artery intima-media thickness. No association of vitamin D status 
with radial distensibility was observed. The results from this cross-sectional 
study suggest that serum vitamin D levels could aff ect vascular structural and 
functional properties and the results also suggest that various vascular territo-
ries could be aff ected diff erently.
There is accumulating evidence that vitamin D defi ciency is associated 
an increased risk for cardiovascular disease. Large population based studies 
have previously shown an association between poor vitamin D status and an 
increased risk of cardiovascular events and cardiovascular related mortality, and 
have also suggested that vitamin D  could be important in the prevention of 
vascular calcifi cation(8). Arterial stiff ness increases with age and is a predictor 
of morbidity and mortality(9). Well established risk factors for arterial stiff ening 
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are hypertension, diabetes mellitus and inflammation(10). However, a role for 
vitamin D in the process of arterial stiffening has also been suggested(8). Several 
studies reported on the association between serum 25(OH)D levels and arterial 
stiffness. In the Baltimore Longitudinal Study of Aging, a prospective study of 
normative aging, vitamin D status was inversely associated with carotid-femoral 
pulse wave velocity (PWV) in a cohort of 1228 healthy volunteers with a mean 
age of 70 years(6). A recent cross sectional study by Mayer et al. in a relatively 
young population (mean age 52.8 years)  reported an association between 
vitamin D status and aortic pulse wave velocity(5).
The exact role of vitamin D in cardiovascular health and specifically the role 
in arterial stiffening is thought to be multifactorial. Both animal and human 
studies have shown that vitamin D metabolites are a negative regulator of the 
renin-angiotensin-aldosterone system (RAAS)(11). The RAAS is involved in main-
tenance of blood pressure, electrolyte homeostasis and control of intravascular 
volume. Large prospective studies have shown an association between low vi-
tamin D levels and increased activity of RAAS which may result in hypertension 
and increased water intake and sodium absorption(11). Furthermore, vitamin D 
metabolites are thought to directly alter myocyte contractility and prolifera-
tion(12). Effects of vitamin D have also been reported on endothelial function, 
regulation of vascular endothelial growth factor (VEGF) production and on 
insulin and glucose handling(4). 
It has previously been reported that vascular stiffening can differ between 
various vascular regions. In a study by Ruitenbeek et al. we found that age and 
blood pressure influenced functional properties of the elastic central arteries 
but not the muscular peripheral arteries(7). Based on the results of the pres-
ent study, it can also be hypothesized that central and peripheral arteries are 
affected differently by vitamin D deficiency in regard to their functional and 
structural properties as associations are observed with carotid distensibility and 
IMT, while no association is observed with radial distensibility. 
Our study has several limitation. First, given the relatively small number of par-
ticipants generalizability is limited. Second, the observational, cross-sectional 
design of the study precludes definitive conclusions regarding causality. Third, 
no information was available on the use of lipid lowers medication.
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In conclusion, in a group of older men and women from the outpatient clinic, 
serum 25(OH)D level was associated with both structural and functional proper-
ties of the carotid artery. No association was observed with the radial artery 
distensibility.
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General dIsCussIon
The main objective of this thesis was to gain more knowledge about the impor-
tance of vitamin D for older individuals in regard to functionality, with an em-
phasis on muscle, cardiovascular and neurological function. Vitamin D research 
has a long history. In the year 1922 the Dutch orthopedic surgeon Havinga 
published an extensive review on rickets in the Dutch language(1). The author 
aimed to summarize the current knowledge on rickets whilst the literature in 
those days is already getting “too extensive for a person to comprehend”. In the 
1920’s it was already established that the risk of developing rickets is related to 
latitude and a link with exposure to sunlight was suggested. Even then, certain 
effects outside bone tissue were already documented in children with rickets, 
such as specific muscle abnormalities. Treatment options in those days con-
sisted mainly of salt baths and hot towel compression therapy, but the positive 
effects of exposure to sunlight or a quartz lamp were started to be recognized. 
The author concluded with the sentence: “Dove non viene il sole, vien’il medico”; 
which can be translated as: “where the sun doesn’t shine, the doctor appears”. Not 
long after the publication of this review, the hormone vitamin D is discovered 
by the American biochemist Elmer V. McCollum. In the forthcoming decades 
vitamin D research would develop gradually, and the importance of vitamin D 
for various disease states in old age would be increasingly recognized. 
The main findings of this thesis are:
•	 Ageing increases the risk of vitamin D deficiency and is associated with 
changes in the calcium homeostasis which impairs the efficacy of the cal-
cium homeostatic process 
•	 The prevalence of vitamin D deficiency among older persons is still high 
despite strong attention for this hormone in recent years
•	 Public knowledge on vitamin D is poor and the level of knowledge is related 
to their vitamin D status 
•	 There is a strong increase in incidence rates of both vertebral fractures and 
hip fractures in the oldest-old (>80 years) in recent years
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•	 Vitamin D status in observational studies is related to various functional 
outcomes in older people such as muscle strength, mobility, cognitive per-
formance and specific cardiovascular measures
•	 High dose vitamin D supplementation is effective in raising serum 25OHD3 
levels in older persons and this dose is well tolerated
•	 High dose vitamin D supplementation in vitamin D deficient older persons 
improves gait speed
The main findings mentioned above are discussed in more detail in this 
chapter. Furthermore, methodological considerations concerning the main 
study outcomes are discussed. Finally, recommendations for future research are 
presented. 
maIn FIndInGs
the effects of ageing on calcium homeostasis and the vitamin 
d endocrine system
In the review in chapter 2.1 we summarized the effects of ageing on both the 
vitamin D endocrine system and calcium homeostasis. Ageing has considerable 
effects on both processes, which impairs their efficacy, leading to specific vul-
nerabilities in older people. Essential is the increased prevalence of vitamin D 
deficiency in old age. This is caused by both a decreased cutaneous production 
of vitamin D due to age related changes in the skin and life-style alterations 
such as less time being spent outdoors, and specific dietary changes. Other age-
related changes are an altered metabolism of the various vitamin D metabolites 
and altered target tissue responsiveness to vitamin D(2). 
In older individuals there is also a decrease in intestinal and renal calcium 
(re)absorption. In part, this decrease in efficiency of the calcium homeostatic 
process observed in elderly is vitamin D related. For example, the expression of 
intestinal calcium channels, necessary for intestinal calcium absorption, is up 
regulated by vitamin D. So, a state of vitamin D deficiency leads to a decrease 
in intestinal calcium channel expression and thus impairs calcium absorption 
leading to a negative calcium balance. However, the decreased intestinal cal-
cium channel expression in older persons cannot entirely be explained by the 
occurrence of vitamin D deficiency. Some studies suggest that sex hormones 
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also stimulate intestinal calcium channel expression and the decrease in serum 
levels of sex hormones in older persons could contribute to the decrease in 
calcium channel expression(3).
In conclusion, the effects of ageing on the vitamin D endocrine system and 
calcium homeostatic process are complex. The effects impair the efficiency of 
both processes leading to specific vulnerabilities in older people either directly 
because of the vitamin D deficiency or because of the negative calcium (and 
phosphate) balance. The health consequences are diverse given the pleiotropic 
effects of the vitamin D hormone. 
Prevalence of vitamin D deficiency and the interrelation with 
health knowledge
In our study, a cross sectional study among older individuals living in residen-
tial care facilities, 67% (285/426) of the participants were vitamin D deficient 
with a serum 25OHD3 level < 50nmol/l. Of those, 27% (115/426) had a serum 
25OHD3 level < 25nmol/l. The results of this study demonstrate that despite 
the implementation of guidelines and the increasing attention for vitamin D in 
both research and media during the past decade, the prevalence of vitamin D 
deficiency among older persons in the Netherlands remains high. In a search for 
causes for this persisting high prevalence of vitamin D deficiency, we studied if 
health knowledge, and more specifically knowledge on vitamin D, was related 
to vitamin D status. In a cohort of older people living in residential care homes, 
we observed an association between knowledge (awareness) on vitamin D and 
serum 25OHD3 concentration. Patients with the best knowledge on vitamin D 
had higher serum 25OHD3 levels as compared to individuals who had the least 
knowledge. This study also demonstrated that overall, general knowledge on 
vitamin D among older persons is poor. Only 38% of the participants indicated 
that they knew or had heard of vitamin D. Among those that knew about vita-
min D, there were many misconceptions or false believes regarding sources and 
effects of vitamin D. To date, mostly studies that examine knowledge on vitamin 
D in younger age groups have been published. In these studies awareness of 
vitamin D ranged from 70% to 97%(4-6). The cause for this observed difference 
between older and younger individuals on awareness of vitamin D is not known 
but limited access to information (newspapers, internet), sensory impairment 
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(poor vision and hearing) and cognitive impairment could play a role. Interest-
ingly, these studies also reported many misbelieves regarding sources and 
effects of vitamin D in young individuals. 
Given the fact that there seems to be a general lack of knowledge on vita-
min D, improving public knowledge might be an intervention strategy in the 
prevention of vitamin D deficiency. However, the possible association between 
knowledge on vitamin D and vitamin D status in older persons is still subject of 
debate. Both knowledge and attitude towards vitamin D are considered as pre-
requisites to specific health behavior. The interrelation between these variables 
seems complex. A previous study reported no association between knowledge 
and five vitamin D related behaviours (all actions people can take to improve 
vitamin D status)(7). Furthermore, a Chinese study found that individuals with 
the best awareness on the possible benefits of sunlight and the importance 
of vitamin D for human health tended to avoid sun exposure(6). In addition, a 
study in the USA found no effect of an increased knowledge of vitamin D on the 
dietary intake of vitamin D(8). 
time trends of the most common fractures among older 
persons
In this thesis we studied secular trends on the most common fractures in older 
individuals: vertebral fractures and hip fractures. These type of fractures are 
strongly associated with osteoporosis, for which vitamin D deficiency is an im-
portant risk factor. Trend analyses of the number of patients with a hip fracture 
over the last decades demonstrated a strong increase in fracture numbers until 
the mid-nineties. Since then, the increase in incidence rates of hip fractures 
started to slow down. Over the last decade, the overall incidence rate has even 
started to decrease. This trend has also been observed in several other coun-
tries(9, 10). Interestingly, in our study there was a difference observed between 
the various age groups. While incidence rates in the younger age groups (<80 
years) decreased, the incidence rates in the oldest old (> 80 years) still increased. 
A cause for this difference in trends that seems age related is not known. For the 
number of vertebral fractures seen at the emergency room over the last decades 
we observed a strong increase in all age groups. However, also with this fracture 
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type there was an age related trend observed: the strongest increase was seen 
in the oldest individuals (>80 years). 
Vertebral and hip fractures are the most common fractures among older per-
son(11). Especially a hip fracture is typically associated with ageing, with approxi-
mately 85% of all hip fractures occurring in individuals aged ≥65 years(12). Hip 
fractures are, more than any type of fracture, associated with loss of indepen-
dence, morbidity and mortality(13). Vertebral fractures are, just like hip fractures, 
associated with functional impairment and mortality. Over 90% of the vertebral 
fractures are associated with osteoporosis. A previous vertebral fractures is a 
strong predictor for a new vertebral fracture, but also for a hip fracture(14). So, 
fracture prevention, including timely treatment of the underlying risk factors of 
both fracture risk and fall risk is of the utmost importance. 
In recent years many care plan and protocols regarding fracture prevention 
have been implemented(15). While this seems successful in the reduction of 
incidence rates of fractures, especially hip fractures in relatively young people, 
the effects in the oldest old seems to fall behind. The cause of these trends is 
not known, but they demonstrate a need for more focus on the optimalization 
of bone health in these older individuals. For the optimalization of bone health 
and the prevention of diseases like osteoporosis, the timely diagnosis and 
subsequent of vitamin D deficiency plays a crucial role, as this is a well-known 
risk factor for osteoporosis. Furthermore, fall risk should also be assessed in 
patients with a fracture after a fall. In the fall risk assessment, the diagnosis and 
treatment of vitamin D deficiency is also included(16). So, improving vitamin D 
status in older individuals could potentially be a cheap and safe intervention to 
reduce fracture rates in the oldest old as still many patients, most likely, remain 
untreated. 
Vitamin d and functional performance, with an emphasis on 
muscle, neurological and cardiovascular function
Muscle function
Even in healthy individuals there is considerable loss of skeletal muscle mass 
and strength (sarcopenia) with ageing. This process is further aggravated by 
an unhealthy (sedentary) life style and by diseases(17). Commonly with muscle 
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ageing, the terminology of extrinsic or intrinsic age effects is used. These refer 
to extrinsic (e.g. hormonal changes and inflammatory effects) and intrinsic (e.g. 
telomere shortening or mitochondrial DNA damage) effects to the muscle cells 
or satellite cells(18). Since the discovery of VDR expression in skeletal muscle 
tissue, hypovitaminosis D is regarded as an important extrinsic factor that con-
tributes to the process of sarcopenia with ageing. 
In recent years, many studies have been performed on vitamin D and muscle 
function. Evidence from observational studies is generally consistent and shows 
an association between vitamin D status and various measures of physical 
performance such as quadriceps strength, handgrip strength, balance and gait 
speed(19). Generally, some signs and symptoms of musculo-skeletal dysfunc-
tion such as falls are especially prevalent among older women suggesting that 
muscle performance in men and women might be affected differently by states 
of vitamin D deficiency. Furthermore, some recent observational studies failed 
to find an association between functional performance in men and vitamin 
D status, questioning the importance of vitamin D for muscle performance in 
men(20). However, our study demonstrated that functional performance is asso-
ciated with vitamin D status in both men and women suggesting that functional 
performance in both men and women is equally affected by vitamin D status. 
This is an important insight in order to prevent under-diagnosis and –treatment 
of vitamin D deficiency in men. In a closely related disease, namely male osteo-
porosis, this has happened until fairly recent, resulting in an underestimation of 
the fracture risk in men. 
While the results of observational studies on vitamin D and muscle function, 
especially in women, seem fairly consistent, the result of intervention studies 
are far less consistent. A recent extensive umbrella review of 87 meta-analyses of 
randomized controlled trials that studied the effect of vitamin D supplementa-
tion on 137 different clinical endpoints concluded that there was considerable 
doubt regarding a possible role of vitamin D in almost all clinical endpoints(21). 
The authors of this review concluded that the argument that vitamin D supple-
mentation reduced the risk of falls or improved muscle performance measures 
in older people was doubtful. The evidence regarding a possible effect on 
muscle strength was classified as “suggestive”. This contrasts with previous 
reports that suggested a more clear effect of vitamin D on muscle strength, 
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physical performance, gait speed and balance(22, 23). The proposed causes for 
the inconsistencies observed between various vitamin D intervention trials are 
variation in study population, number of participants (lack of sufficient power), 
variation in baseline vitamin D status and functional performance, variation in 
intervention duration and variation in supplementation dose. Especially the 
effective supplementation dose (or optimal serum 25OHD3 level for muscle 
function) has been subject of debate. Recent studies suggested that a serum 
25OHD3 level of 75- 90nmol/l is preferable for optimal muscle function
(24, 25). 
This serum concentration, however, is not reached in most trials. In our study, 
a high supplementation dose was used of 1800IU/day, for six months. This re-
sulted in a mean serum 25OHD3 level of 107 nmol/l. This supplementation dose 
was well tolerated. In this study an improvement in gait speed and timed up go 
(TUG) performance was observed, while no effect on muscle strength was ob-
served. The observed results contrast some previous reports but are in line with 
other intervention trials(26, 27). In our study gait speed improved with about 8%, 
while in absolute measures, the mean improvement was 0.08m/s. These results 
demonstrate that there is at least some effect of vitamin D supplementation on 
functional performance. However, in the literature, a clinical relevant change in 
gait speed is regarded to be at least an improvement of 0.1m/s making the clini-
cal relevance of the observed effect questionable. Furthermore, previous stud-
ies also suggested an improvement of muscle strength and performance with 
vitamin D supplementation of about 8%. These trials, however, used a relatively 
low dose vitamin D supplementation of mostly 400IU- 800IU/day. Therefore, the 
observed effect in our study make the additional effect and necessity of high 
dose supplementation less clear as the functional improvement in our study 
was not superior to the improvement observed in low(er) dose supplementa-
tion trials(26). 
Cardiovascular function
The hypothesis that vitamin D status is associated with cardiovascular health 
seems plausible given the wide distribution of the VDR among tissues involved 
in blood pressure regulation(28). However, importance of vitamin D for car-
diovascular health is still not clear. Possible roles for vitamin D are still being 
unraveled. In our study we found an association between vitamin D status and 
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carotid intima media thickness (IMT) while no association was observed with 
radial IMT. Based on the results of this study it can be hypothesized that various 
blood vessels, either central or peripheral, are affected differently by vitamin D. 
Correct understanding of the significance of vitamin D for cardiovascular health 
is important to eventually understand both the risk of both vitamin D deficiency 
and also vitamin D supplementation for cardiovascular health. 
In recent years various studies have been published that further complicate 
the possible role of vitamin D in cardiovascular health. In studies published by 
Durup et al. and Wang et al., a non-linear relationship between serum 25OHD3 
and cardiovascular disease was reported(29, 30). Additionally, a recent study from 
the Netherlands by van Dijk et al. reported a non-linear association between 
serum 25OHD3 and carotid IMT and pulse wave velocity (PWV)
(31). In particular, 
above  levels of 50nmol/l there was a slight increase of IMT with increasing 
25OHD3 levels. This seems in line with the studies by Durup et al. and Wang et al. 
who reported a nadir around 60nmol/l in the risk curve between vitamin D sta-
tus and cardiovascular disease and mortality. This uncertainty, concerning the 
possible non-linear association between vitamin D and cardiovascular disease, 
warrants some restraints in the use of high dose vitamin D supplementation. 
Especially given the fact that the additional benefit of high dose supplementa-
tion is still not proven and that the clinical experience with prolonged high dose 
vitamin D supplementation is still limited, both in young and old individuals. 
Neurological function 
In this thesis we demonstrated an association between vitamin D status and 
cognitive functioning in patients with symptoms of cognitive dysfunction. Since 
the study by Eyles et al. on the wide distribution of the VDR expression and the 
detection of the various vitamin D metabolites, the central nervous system is 
regarded a target tissue for vitamin D(32). In animal models there seems clear 
evidence for the involvement of vitamin D in the normal neurological and brain 
development(33). A recent study suggested that the threshold of 25OHD3 associ-
ated with cognitive impairment is around 25nmol/l  (25nmol/l), persons with 
25OHD3 concentrations <25nmol/l having a greater risk of cognitive disorders 
than those with 25OHD3 levels >10ng/ml
(34).
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However, to date, most clinical evidence on the importance of vitamin D for 
neurological function and more precise, cognitive function, comes from obser-
vational (cross-sectional) data. In our study there was a clear association be-
tween cognitive function and vitamin D status. It can therefore be hypothesized 
that vitamin D status is important for cognitive functioning, even in patients 
with memory complaints. In in vitro and ex vivo studies effects of vitamin D 
have been reported on neurotrophin levels, neurotransmitter production and 
free radical (nitric oxide) production which could affect cognitive function, 
strengthening the hypothesis that vitamin D is important for normal neurologi-
cal functioning(35). It should be noted, however, that given the cross-sectional 
nature of our study, no causality could be concluded. In these cross-sectional 
studies, there is always the possibility of reverse causality (see limitation sec-
tion). 
methodoloGICal and theoretICal Issues
observational vitamin d data
Observational studies, no matter how well prepared or controlled, are still 
potentially subject to some methodological issues. This is a particular problem 
for observational data from vitamin D related studies. Firstly, almost all disease 
states are likely to reduce and persons’ level of physical activity and therefore 
altering exposure to sunlight. This introduces the possibility of reverse causality 
in these studies. This issue affects all cross-sectional and longitudinal studies 
with short follow-up times. Secondly, several risk factors for disease states such 
as sarcopenia, dementia and cardiovascular disease are also known to lead 
to vitamin D deficiency. These risk factor include ageing, unhealthy diet and 
smoking. Low serum 25OHD3 levels could therefore possibly be a “bystander” 
(confounder).
use of administrative databases
High quality electronic databases (the National Hospital Discharge Registry and 
the Dutch Injury Surveillance System) used for the fracture trend analyses in 
this thesis enable studies for trend analysis on specific topics over a long period. 
There are some limitations however. First of all, the data are only accurate within 
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the limitations of the coding system. The accuracy of the hospital information is 
likely to be dependent on the accuracy of the data in the medical records and 
the recognition of the injuries by the patient’s physician and secondly by the 
clerk coding the diagnosis into the database. A second limitation of the admin-
istrative databases is that the databases do not contain information regarding 
factors such as underlying co-morbidities, drug use and clinical details of the 
individual patients(36).
Implications for clinical practice and future research
The studies in this thesis demonstrate that older persons are at risk for vitamin 
D deficiency and various other age related effects that increase fall and frac-
ture risk. We demonstrated that especially in the oldest old (age ≥ 80 years) 
incidence rates of hip and vertebral fractures are increasing sharply in recent 
years. We also demonstrated that the prevalence of vitamin D deficiency is still 
high in these age groups. The high prevalence of vitamin D deficiency seems 
to persist despite the fact that the deleterious effects of vitamin D deficiency 
are well known and also despite the introduction of many guidelines, protocols 
and care plans on the screening and treatment of vitamin D deficiency. Given 
the observed trend in fracture rates, healthcare providers should focus more on 
this age group with regard to prevention of falls and fractures. The diagnosis 
and treatment of vitamin D deficiency in older individuals in this regard is es-
sential. Future research should focus on factors related to the persisting high 
prevalence of vitamin D deficiency. In this regard, we demonstrated that there 
is a clear lack of knowledge among older individuals on vitamin D. It can be hy-
pothesized that providing information on vitamin D to older people eventually 
leads to an improvement of vitamin D status and reduction in fracture rate. This 
hypothesis should be tested in future studies to develop an effective method 
to inform older persons. An effective method to inform the older population is 
not known at the moment and is most likely subject to change, given the recent 
technological advances. 
In this thesis we also focused on the association between functionality and 
vitamin D in older individuals and more specifically the association with muscle 
function, cognitive function and cardiovascular function. In the section on 
vitamin D and muscle function we demonstrated that there is an association 
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between vitamin D status and muscle strength and mobility in both in men and 
women. Previous intervention studies on the effect of vitamin D supplementa-
tion show conflicting results with regard to muscle function. While this, in part 
could be due to methodological issues such as trial duration or participant 
selection, it has also been hypothesized that the supplementation dose in 
previous trials was too low. In a high dose intervention we saw improvement 
in gait speed and TUGT performance, while there was no effect on muscle 
strength. However, the clinical relevance of the observed effect was doubtful 
and did not seem superior when compared to normal or low dose vitamin D 
supplementation. So, while the trial results suggest there is at least some revers-
ibility of the prolonged effects of hypovitaminosis D on muscle function with 
vitamin D supplementation, new trials on the effect of vitamin D are needed. 
Especially trails with a long observation period are urgently needed. These trials 
should also deal with other methodological issues of previous studies such as 
population heterogeneity, study power, variation in baseline vitamin D status 
and functional performance and supplementation dose.  
In addition, we also demonstrated associations between vitamin D status 
and cardiovascular health and cognitive functioning. The observed associations 
strengthen the hypothesis that vitamin D could be associated with various 
disease states outside the musculo-skeletal system. So, future trials should ide-
ally have a holistic approach on the possible effects of vitamin D and define 
a serum vitamin D level that is optimal for all target tissues. For example, the 
optimal serum vitamin D level or supplementation dose for muscle function is 
not necessarily the same as for cardiovascular health or neurological function-
ing. Future trials, especially those that use high dose supplementation should 
therefore include multiple endpoints of various organ systems and use a more 
holistic approach.
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6.1
Functional performance declines with ageing. During the ageing process all tis-
sues and organ systems decline in function, resulting in a decreased functional 
reserve and a state of increased vulnerability. In this regard, vitamin D seems of 
particular interest because of the pleiotropic function of this hormone which in-
clude effects on muscle, bone, neurons and vascular tissue. Additionally specific 
age-related changes occur with regard to vitamin D and calcium homeostasis 
leading to specific risks and deficiencies in older individuals which contribute to 
the occurrence of functional decline in older individuals.
Section 1 gives a general introduction on the research topics of this thesis. 
Section 2, Chapter 2.1 provides a review of the specific age related changes that 
occur in the vitamin D endocrine system and calcium homeostatic process. Es-
sential is the increased prevalence of vitamin D deficiency in older individuals. 
This is caused by both a decreased cutaneous production of vitamin D due to age 
related changes in the skin and life-style alterations such as less time being spent 
outdoors and specific dietary changes. In Chapter 2.2 the prevalence of vitamin 
D deficiency and the interrelation with health knowledge is presented. In older 
individuals living in residential care 67% (285/426) had a vitamin D deficiency 
(serum 25OHD3 level of <50nmol/l). There was a clear association between vi-
tamin D related health knowledge and vitamin D serum level: participants who 
indicated that they knew vitamin D had a higher serum vitamin D level than 
those who indicated never to have heard of vitamin D. In total, only 38% of the 
participants indicated that they knew or had heard of vitamin D. Among those 
that indicated that they knew vitamin D, there were many misconceptions and 
false believes regarding the sources and effects of vitamin D. In Chapter 2.3 and 
2.4 we present secular trends on the most common fractures in older individu-
als: vertebral fractures and hip fractures. These fractures are strongly associated 
with osteoporosis, for which vitamin D deficiency is an important risk factor. In 
Chapter 2.3 the number of hip fractures in the Netherlands is presented. The in-
cidence of hip fractures increased  rapidly until the mid-nineties. Since then, the 
increase in incidence rates of hip fractures started to slow down. Over the last 
decade, the overall incidence rate has started to decrease. There was a difference 
observed between the various age groups however. While incidence rates in the 
younger age groups (<80 years) decreased, the incidence rates in the oldest old 
(> 80 years) still increased. The cause of this trend is not known. In Chapter 2.4 
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the number of acute vertebral fractures leading to an Emergency Department 
visit in the Netherlands are shown. Overall, the number of vertebral fractures 
increased strongly over the past decades in almost all age groups. However, 
also with vertebral fractures, the strongest increase was seen in the oldest old. 
Overall, these observations demonstrate the need for more emphasis on falls 
and fracture prevention in the oldest old.
In Section 3, the interrelation between vitamin D and functional performance 
in older individuals is studied, with a focus on muscle, neurological and car-
diovascular function. Firstly, in Chapter 3.1 the association between vitamin 
D status and physical performance in older individuals is presented. In our 
study, an association between functional performance and vitamin D status 
was observed in both men and women. This study negates the hypothesis that 
there is no association between vitamin D status and functional performance 
in men. In Chapter 3.2 the effect of high dose vitamin D supplementation on 
neuromuscular function is shown. High dose supplementation (1800IU/day) for 
six months was well tolerated and was effective in raising serum 25OHD3 levels. 
The intervention lead to an improvement in gait speed and timed up and go 
performance. No improvement in muscle strength was observed. The observed 
effect however was relatively small and not greater than in previous low dose 
intervention studies. In Chapter 3.3 the association between vitamin D status 
and cognitive performance is presented. In this chapter we demonstrated an 
association between cognitive performance and vitamin D status in patients 
with cognitive impairment.
In Section 4 the association between vitamin D status and vascular function 
is studied. The finding in this study indicates that various vascular regions in 
the body could be affected differently by states of vitamin D deficiency, dem-
onstrating that the association between vascular health and vitamin D status is 
complex. Correct understanding of the interrelation between vitamin D status 
and vascular function is important because some studies previously reported 
an U-shaped association between vitamin D status and vascular health, where 
both very low and very high serum levels lead to an increased risk for vascular 
disease.
In Section 5, the general discussion, the main findings of this thesis are 
discussed and put in a broader perspective. The results indicate that vitamin 
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D deficiency is still prevalent among older individuals and that knowledge 
among older individuals about vitamin D is poor. With regard to functional 
performance we demonstrated an association between vitamin D status and 
muscle performance in both men and women. High dose vitamin D supplemen-
tation improves neuromuscular function (gait speed and TUGT performance) 
and is well tolerated. In addition associations were also observed with cognitive 
performance and vascular function. Future research should focus on defining 
the optimal serum vitamin D level or supplementation dose. 

Chapter 6.2
Samenvatting en conclusies
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Tijdens het verouderingsproces treedt er functieverlies op. Veroudering result-
eert in achteruitgang van de verschillende orgaanfuncties waardoor er minder 
functionele reserve is en de kwetsbaarheid van een individu toeneemt. Hierbij 
speelt ook het hormoon vitamine D een belangrijke rol, vanwege de pleiotrope 
functies van dit hormoon, dat effecten heeft op onder andere spieren, botten, 
neuronen en bloedvaten. Het vitamine D-endocriene systeem en de calcium 
homeostase zijn aan bepaalde leeftijdsgerelateerde verouderingseffecten on-
derhevig die kunnen bijdragen aan het optreden van functieverlies tijdens het 
verouderingsproces. 
Sectie 1 geeft een algemene introductie op de onderwerpen van dit proef-
schrift. Sectie 2, Hoofdstuk 1 beschrijft een review over de specifieke leeftijds-
gerelateerde veranderingen die optreden binnen het vitamine D-endoriene 
systeem en de calcium homeostase. Essentieel hierin is de hoge prevalentie 
van vitamine D deficiëntie onder ouderen. Dit ontstaat met name door een 
verminderde productie van vitamine D in de huid door leeftijdsgerelateerde 
veranderingen in de huid, en door  veranderingen in levensstijl waaronder het 
minder buiten zijn, en veranderingen in het dieet. In Hoofdstuk 2.2 wordt de 
prevalentie van vitamine D deficiëntie beschreven, evenals de samenhang tus-
sen vitamine D deficiëntie en de specifieke kennis van ouderen over vitamine D. 
Bij onderzoek onder oudere personen wonend in een verzorgingshuis, bleek bij 
67% (285/426 personen) sprake van een vitamine D deficiëntie (serum 25OHD3 
concentratie < 50nmol/l). Er was een duidelijke associatie tussen de kennis die 
een oudere had omtrent vitamine D en de serum 25OHD3 concentratie: per-
sonen die aangaven vitamine D te kennen hadden een hogere serum 25OHD3 
concentratie dan personen die aangaven vitamine D niet te kennen. In totaal gaf 
slechts 38% van de participanten aan vitamine D te kennen. Echter, onder deze 
personen, die wel aangeven hadden vitamine D te kennen, bestonden voorts 
veel misvattingen over zowel  de mogelijke bronnen als de werking (effecten) 
van vitamine D. Hoofdstuk 2.3 en 2.4 richten zich op trendontwikkelingen van 
de meest voorkomende typen fracturen bij ouderen: wervelfracturen en heu-
pfracturen. Het risico op het optreden van deze beide type fracturen is sterk 
geassocieerd met osteoporose. Vitamine D deficiëntie is op zijn beurt weer een 
zeer belangrijke risicofactor voor het ontwikkelen van osteoporose. Hoofdstuk 
2.3 beschrijft de prevalentie van heupfracturen in Nederland. De incidentie van 
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het aantal heupfracturen in Nederland steeg sterk tot ongeveer het midden 
van de 90-er jaren. Nadien begon de incidentie van heupfracturen geleidelijk 
te dalen. Er is hierin echter wel een verschil waarneembaar tussen verschillende 
leeftijdsgroepen. Hoewel de incidentie in relatief jongere leeftijdsgroepen (<80 
jaar) daalde, nam de incidentie nog steeds toe in oudere leeftijdsgroepen (>80 
jaar). De onderliggende oorzaak van dit verschil is niet bekend. In Hoofdstuk 
2.4 wordt het aantal nieuwe wervelfracturen beschreven waarvoor een bezoek 
aan de Eerste Hulp noodzakelijk is. Over het algemeen neemt het aantal wervel-
fracturen, in vrijwel alle verschillende leeftijdsgroepen, sterk toe gedurende de 
laatste tientallen jaren. Echter, ook hier valt op dat het aantal wervelfracturen 
het sterkst toeneemt bij de oudste-ouderen. De resultaten van deze studies 
laten zien dat er met name meer aandacht moet zijn voor de preventie van 
zowel valincidenten en fracturen, vooral in deze oudste leeftijdsgroepen. 
In Sectie 3 wordt de relatie tussen vitamine D status en functionaliteit bij 
ouderen bestudeerd. Hierin wordt er een focus gelegd op spierfunctie, neu-
rologische functie en cardiovasculaire functie. Allereerst wordt in Hoofdstuk 
3.1 de associatie tussen vitamine D status en spierfunctie beschreven. In onze 
studie werd een associatie gevonden tussen vitamine D status en spierfunctie 
in zowel mannen als vrouwen. Deze studie ontkracht de hypothese dat vita-
mine D niet belangrijk is voor spierfunctie bij mannen. In Hoofdstuk 3.2 wordt 
het effect van suppletie met een hoge dosis vitamine D suppletie gedurende 6 
maanden onder ouderen wonend in verzorgingshuizen beschreven. De hoge 
dosis suppletie (1800IE/dag) werd goed verdragen en was effectief voor de 
behandeling van vitamine D deficiëntie. De behandeling resulteerde in een 
verbetering van de loopsnelheid en van de scores op de Timed-Up-and- Go-Test 
(TUGT). Er werd geen effect op spierkracht gevonden. Het waargenomen effect 
was relatief klein en niet groter dan bij eerdere studies die een lagere dosering 
vitamine D gebruikten. Hoofdstuk 3.3 beschrijft de associatie tussen vitamine 
D status en cognitieve functies. In dit hoofdstuk tonen we een associatie aan 
tussen vitamine D status en cognitieve functie bij patiënten die reeds geheu-
genklachten hebben.
In Sectie 4 wordt de associatie tussen vitamine D status en cardiovasculaire 
functie bestudeerd. De resultaten van deze studie duiden erop dat verschil-
lende vasculaire regio’s in het lichaam verschillend worden beïnvloed door het 
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optreden van een vitamine D deficiëntie, wat erop lijkt te wijzen dat de associa-
tie tussen vitamine D en cardiovasculaire functie complex is. Echter, een goed 
begrip van de samenhang tussen vitamine D status en cardiovasculaire functie 
is van groot belang. Enkele eerdere studies beschreven een U-vormige associa-
tie tussen vitamine D status en cardiovasculaire functie. Hierbij zou zowel een 
sterk verlaagde, als een sterk verhoogde serum vitamine D waarde een negatief 
effect op de cardiovasculaire functie, en gezondheid hebben. 
In Sectie 6 worden de belangrijkste bevindingen van dit proefschrift in een 
breder perspectief geplaatst. De resultaten geven aan dat vitamine D defi-
ciëntie nog steeds erg vaak voorkomt bij ouderen en dat hun kennis omtrent 
vitamine D matig is. Met betrekking tot functionaliteit bij ouderen toonde dit 
proefschrift een associatie aan tussen vitamine D en spierfunctie, bij zowel man-
nen als vrouwen. Hoog gedoseerde vitamine D suppletie onder ouderen in het 
verzorgingshuis resulteerde in een verbetering van spierfunctie (loopsnelheid 
en TUGT score). Verder werden er ook associaties gevonden tussen vitamine D 
status en cognitieve functies, en vitamine D status en diverse cardiovasculaire 
functies. Vervolgonderzoek is noodzakelijk, met name om de optimale vitamine 
D status of supplement dosis te bepalen. 
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dankWoord / aCknoWledGements
Nu, iets meer dan 8 jaar na het starten van mijn promotie traject ben ik toe aan 
het schrijven van mijn dankwoord. Het is een lange weg geweest die niet altijd 
even makkelijk was. Toch kijk ik, nu het proefschrift is afgerond, met genoegen 
terug op deze periode. Zonder alle hulp de afgelopen jaren van veel collega’s, 
vrienden, en familieleden was dit proefschrift niet tot stand gekomen. Ik wil 
iedereen die mij de afgelopen jaren geholpen heeft, hiervoor hartelijk danken!. 
Verder geven deze laatste pagina’s mij de gelegenheid enkele personen in het 
bijzonder te noemen.
Geachte professor van der Cammen, beste Tischa, gevat door uw enthousiasme 
heb ik gekozen voor de ouderengeneeskunde. U heeft dit promotie traject 
mogelijk gemaakt, wat uiteindelijk heeft geresulteerd in dit proefschrift. Ik heb 
de afgelopen jaren ontzettend veel van u geleerd, zowel op professioneel als 
persoonlijk vlak: zo ziet u kansen en mogelijkheden waar anderen dat niet zien, 
heeft een bijzondere gave om “out of the box” te denken en als voornaamste: 
geeft u nooit op, ook al is het nog zo lastig. Met veel plezier denk ik terug aan 
alle congresbezoeken, en alle ontmoetingen met personen waar u mij intro-
duceerde. Ook aan de vele avonden waar we, soms aan de keukentafel, mijn 
artikelen corrigeerden, denk in met veel genoegen terug.  
Geachte dr. Colin, beste Edgar, toen we jou vanuit de geriatrie benaderden met 
de vraag of je mijn promotie-traject wilde begeleiden stemde je direct in. Je 
bent al die jaren een onmisbare steun geweest en zonder jou was dit proef-
schrift er uiteraard niet gekomen. Menigmaal ben je helemaal vanuit het oosten 
’s lands naar Rotterdam gekomen voor een overleg. Je kritische blik en soms 
“botte bijl” waren bijzonder scherp. Ook je humor, met niet zelden een licht 
cynische karakter, heb ik bijzonder gewaardeerd!. 
Geachte professor van Leeuwen, beste Hans. Dank dat je mijn promotor wilde 
zijn. Hoewel de geriatrie aanvankelijk niet direct behoorde tot jouw veld van 
expertise, was je altijd bereid mee te denken en je in de materie te verdiepen. 
Verder gebeurde het best wel eens dat ik een deadline niet haalde en was je 
174 | Chapter 6.2
altijd bereid tijd voor me vrij te maken. Ik denk met veel genoegen terug aan de 
gesprekken op jouw kamer waar je altijd in staat was kritische vragen te stellen 
en mij zo aanspoorde tot verdere verdieping.
Geachte dr. Mattace Raso, beste Francesco. We werken nu al vele jaren samen. 
Of het nu is op wetenschappelijk gebied, in de kliniek, of op persoonlijk vlak: je 
bent altijd bereid advies te geven of je hulp aan te bieden. Ik waardeer je steun 
enorm en dat heeft mij ontzettend geholpen om te komen op de positie waar ik 
nu ben. Ik hoop nog vele jaren met je samen te werken en te kunnen genieten 
van je “slechte grappen”.
Geachte dr. van der Velde, beste Nathalie. Toen ik begon bij de geriatrie, als 
opleidings-assistent, en later als promovendus, was jij al bijna in de afrondende 
fase van je proefschrift. We zijn een tijd kamergenoten geweest op de “duiven-
til”, waar ik van nabij zag dat promoveren soms heel hard werken is, maar ook 
ontzettend veel leuke en uitdagende kanten met zich mee kan brengen. Ik heb 
ontzettend veel van je geleerd en ben je dankbaar voor alle hulp de afgelopen 
jaren. Met name ook voor de momenten dat je er als “praatpaal/luisterend oor” 
was!.
Geachte dr. Hartholt, beste Klaas. Op het moment dat er enkele donkere wolken 
boven mijn promotie traject hingen (toen in het lab de cellijnen toch niet zo 
levensvatbaar bleken…) kwam jij als een soort sneltrein voorbij. We hebben sa-
men in korte tijd enkele artikelen geschreven en mede daardoor mijn promotie-
traject weer op de rit gekregen. Verder uiteraard dank voor alle keren dat je me 
hebt bijgestaan met statistisch advies of het maken van een figuur! 
Geachte Prof. dr. A.J. van der Lely, Prof. dr. P. Patka en Prof. dr. P. Lips, hartelijk 
dank voor het zitting nemen in de kleine commissie en voor het inhoudelijk 
beoordelen van mijn proefschrift.
Uiteraard wil ik ook Anke Nijs bedanken. Anke, jij hebt mij als onderzoeksver-
pleegkundige vanuit de reumatologie ontzettend geholpen bij het verrichten 
van de interventie studie. Je niet aflatende enthousiasme en doorzettingsver-
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mogen werkte bijzonder aanstekelijk. De deelnemers spraken altijd bijzonder 
enthousiast over je, en velen genoten van je aanwezigheid!. 
Uiteraard wil ik ook iedereen van het reuma lab bedanken: Erik, Anne-Marie, 
Ferry, Sonja, Lisette en uiteraard: Patrick. Patrick, als mede Dordtenaar, bedankt 
voor alles wat je de afgelopen jaren hebt gedaan! Bij bijvoorbeeld het kweken 
van cellen, het verrichten van ELISA’s en het analyseren van de data. Ik heb veel 
geleerd van je en ik kijk met heel veel plezier terug naar de tijd op het lab!.
Verder wil ik natuurlijk ook alle bewoners en medewerkers van de zorginstel-
lingen bedanken die ons geholpen hebben de onderzoeken mogelijk te maken. 
Hierin gaat mijn dank in het bijzonder uit naar Romke van Balen. Romke, doordat 
jij bereid was ons te helpen met het opstarten van de studie was het uiteindelijk 
mogelijk hieraan een vervolg te geven.
Ook wil ik alle co-auteurs bedanken die hebben meegeholpen aan het schrijven 
van de artikelen waarop dit proefschrift is gebaseerd. 
Beste vrienden en familie, uiteraard wil ik jullie ook bedanken voor de steun de 
afgelopen jaren. Met name ook mijn “broertje” voor alle keren dat hij te hulp 
moest schieten. Ar, bedankt voor alle steun!
Ik ben ontzettend blij dat mijn paranimfen, Rozemarijn en Raymond mij bij wil-
len staan tijdens de verdediging van mijn proefschrift. Rozemarijn, als kamerge-
noot heb jij de laatste jaren van mijn promotie van nabij meegemaakt. Wat er 
ook is, ik kan je altijd om hulp vragen, en je komt altijd met een oplossing!. Met 
name je lijstjes met probleem-oplossende antwoorden zijn een enorme steun 
geweest de afgelopen jaren.
Raymond, waarschijnlijk ben ik verantwoordelijk voor ontstaan van je eerste 
grijze haren, toen je mij zo’n 20 jaar geleden al bijles natuurkunde en wiskunde 
gaf of weer eens de computer moest repareren. Geweldig dat je ook nu mijn 
paranimf wilt zijn!.
Tot slot Anneke, ik wil je bedanken voor alle steun de afgelopen jaren. Er waren 
momenten dat je even genoeg had van “vitamine D” maar als het nodig was 
stond je altijd voor mij klaar. De keren dat je in slaap viel, terwijl ik vol enthousi-
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asme mijn review voorlas ter controle op spelfouten, liggen gelukkig ver achter 
ons…
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